adenine has been researched along with Kidney Failure in 92 studies
Kidney Failure: A severe irreversible decline in the ability of kidneys to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism.
Excerpt | Relevance | Reference |
---|---|---|
"Treatment with tenofovir disoproxil fumarate has been associated with renal toxicity or reductions in bone mineral density, or both, in some patients with chronic hepatitis B virus (HBV) infection." | 9.34 | Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study. ( Agarwal, K; Ahn, SH; Bae, H; Buti, M; Chan, HLY; Chen, CY; Chuang, WL; Flaherty, JF; Fung, S; Gaggar, A; Lampertico, P; Lau, A; Lim, YS; Liu, Y; Ma, X; Ramji, A; Subramanian, GM; Suri, V; Tak, WY; Tam, E; Tan, SK; Trinh, H; Wu, G; Yoon, SK, 2020) |
"80 patients with chronic hepatitis B received the antiviral therapy of adefovir dipivoxil (ADV, 10 mg/d)." | 9.14 | [Efficacy of the 96-week adefovir dipivoxil therapy in patients with chronic hepatitis B]. ( Cao, H; Chen, LB; Li, G; Shu, X; Xie, QF; Xu, QH; Xu, Z, 2010) |
"Adefovir dipivoxil is safe for the treatment of chronic hepatitis B in patients with varying degrees of renal dysfunction and lamivudine-resistant HBV and results in biochemical and virological efficacy similar to that reported in the general population." | 9.11 | Efficacy and safety of adefovir dipivoxil in kidney recipients, hemodialysis patients, and patients with renal insufficiency. ( Brosgart, C; Chaix, ML; Currie, G; Fontaine, H; Morales, E; Nalpas, B; Pol, S; Serpaggi, J; Vallet-Pichard, A; Varaut, A; Verkarre, V, 2005) |
"Tenofovir alafenamide (TAF) has recently been approved for chronic hepatitis B (CHB)." | 8.95 | Tenofovir alafenamide as compared to tenofovir disoproxil fumarate in the management of chronic hepatitis B with recent trends in patient demographics. ( Hsu, YC; Nguyen, MH; Wei, MT, 2017) |
"Previous studies have demonstrated that the treatment of chronic hepatitis B (CHB) infection with adefovir (ADV) can impair renal function." | 7.80 | Telbivudine protects renal function in patients with chronic hepatitis B infection in conjunction with adefovir-based combination therapy. ( Kim, HY; Kim, YJ; Lee, HJ; Lee, HS; Lee, JH; Lee, M; Oh, S; Yeum, TS; Yoon, JH; Yu, SJ, 2014) |
"To investigate the effect of long-term tenofovir disoproxil fumarate (TDF) use on renal function, especially in patients with low body weight who are vulnerable to TDF nephrotoxicity." | 7.80 | Long-term exposure to tenofovir continuously decrease renal function in HIV-1-infected patients with low body weight: results from 10 years of follow-up. ( Aoki, T; Gatanaga, H; Honda, H; Kawasaki, Y; Kikuchi, Y; Kinai, E; Mizushima, D; Nishijima, T; Oka, S; Tanaka, N; Tanuma, J; Teruya, K; Tsukada, K; Watanabe, K; Yazaki, H, 2014) |
"Nephrogenic systemic fibrosis (NSF) is a scleroderma-like disease associated with prior administration of certain gadolinium chelates (GCs)." | 7.79 | Nephrogenic systemic fibrosis-like effects of magnetic resonance imaging contrast agents in rats with adenine-induced renal failure. ( Bouzian, N; Bruneval, P; Corot, C; Daubiné, F; Factor, C; Fretellier, N; Hollenbeck, C; Idée, JM; Jestin, G; Laprévote, O; Mandet, C; Massicot, F; Parmentier, N; Port, M, 2013) |
"Adefovir and tenofovir are nucleotide analogues used as long-term therapy of chronic hepatitis B." | 7.78 | Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B. ( Chong, WH; Collins, MT; Gara, N; Ghany, MG; Hoofnagle, JH; Jake Liang, T; Kleiner, DE; Zhao, X, 2012) |
"This was a retrospective study of human immunodeficiency virus (HIV)-infected patients at a university-affiliated HIV clinic who were prescribed tenofovir between July 1, 2001, and January 31, 2009." | 7.77 | A comparison of tenofovir-associated renal function changes in HIV-infected African Americans vs Caucasians. ( Cocohoba, J; Gruta, C; John, MD; Lao, CK, 2011) |
"The study evaluated whether a liquid suspension of adefovir dipivoxil (ADV) is effective and safe when dose adjusted based on varying degrees of renal impairment in patients with chronic hepatitis B." | 7.77 | Efficacy and pharmacokinetics of adefovir dipivoxil liquid suspension in patients with chronic hepatitis B and renal impairment. ( Frederick, D; Pol, S; Rostaing, L; Rousseau, F; Schiff, E; Shiffman, ML; Thabut, D; Zeuzem, S; Zong, J, 2011) |
"Combination therapy with adefovir dipivoxil (ADV) and lamivudine (LAM) is recommended for patients infected with LAM-refractory hepatitis B virus (HBV)." | 7.76 | Add-on combination therapy with adefovir dipivoxil induces renal impairment in patients with lamivudine-refractory hepatitis B virus. ( Enomoto, M; Habu, D; Imanishi, Y; Iwai, S; Kawada, N; Kobayashi, S; Morikawa, H; Sakaguchi, H; Shiomi, S; Tamori, A, 2010) |
" A 40-year-old liver transplant recipient with hepatitis B virus reinfection, resistance to lamivudine, and fibrosing cholestatic hepatitis complicated by terminal renal impairment and spontaneous bacterial peritonitis was treated with adefovir dipivoxil 10 mg after every dialysis." | 7.72 | Successful treatment of fibrosing cholestatic hepatitis using adefovir dipivoxil in a patient with cirrhosis and renal insufficiency. ( Barg-Hock, H; Becker, T; Bleck, JS; Bock, CT; Böker, KH; Flemming, P; Klempnauer, J; Manns, MP; Rosenau, J; Tillmann, HL; Trautwein, C, 2003) |
"Fanconi syndrome with osteomalacia can develop in patients with chronic hepatitis B infection being treated with adefovir at a conventional low dosage of 10 mg/day." | 5.56 | Osteomalacia and renal failure due to Fanconi syndrome caused by long-term low-dose Adefovir Dipivoxil: a case report. ( Cen, X; Cui, Y; Liu, Z; Mu, G; Xiang, Q; Xie, Q; Yu, Y; Zhang, H; Zhang, J, 2020) |
"Renal failure was assessed by plasma and urinary markers." | 5.43 | The renal mitochondrial dysfunction in patients with vascular calcification is prevented by sodium thiosulfate. ( Krishnaraj, P; Kurian, GA; Ravindran, S, 2016) |
"Adenine-treated animals experienced weight-loss, polyuria and polydipsia; however, these effects were significantly attenuated in adenine-treated Gunn rats." | 5.42 | Endogenously elevated bilirubin modulates kidney function and protects from circulating oxidative stress in a rat model of adenine-induced kidney failure. ( Benzie, IF; Boon, AC; Briskey, D; Bulmer, AC; Coombes, JS; Fassett, RG; Gopalan, V; Lam, AK, 2015) |
"Treatment with tenofovir disoproxil fumarate has been associated with renal toxicity or reductions in bone mineral density, or both, in some patients with chronic hepatitis B virus (HBV) infection." | 5.34 | Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study. ( Agarwal, K; Ahn, SH; Bae, H; Buti, M; Chan, HLY; Chen, CY; Chuang, WL; Flaherty, JF; Fung, S; Gaggar, A; Lampertico, P; Lau, A; Lim, YS; Liu, Y; Ma, X; Ramji, A; Subramanian, GM; Suri, V; Tak, WY; Tam, E; Tan, SK; Trinh, H; Wu, G; Yoon, SK, 2020) |
"80 patients with chronic hepatitis B received the antiviral therapy of adefovir dipivoxil (ADV, 10 mg/d)." | 5.14 | [Efficacy of the 96-week adefovir dipivoxil therapy in patients with chronic hepatitis B]. ( Cao, H; Chen, LB; Li, G; Shu, X; Xie, QF; Xu, QH; Xu, Z, 2010) |
"Adefovir dipivoxil is safe for the treatment of chronic hepatitis B in patients with varying degrees of renal dysfunction and lamivudine-resistant HBV and results in biochemical and virological efficacy similar to that reported in the general population." | 5.11 | Efficacy and safety of adefovir dipivoxil in kidney recipients, hemodialysis patients, and patients with renal insufficiency. ( Brosgart, C; Chaix, ML; Currie, G; Fontaine, H; Morales, E; Nalpas, B; Pol, S; Serpaggi, J; Vallet-Pichard, A; Varaut, A; Verkarre, V, 2005) |
"Tenofovir disoproxil fumarate (TDF), an ester prodrug of tenofovir (TFV), is one of the recommended drugs for chronic hepatitis B (CHB) patients." | 4.98 | Tenofovir alafenamide (TAF) treatment of HBV, what are the unanswered questions? ( Grossi, G; Lampertico, P; Loglio, A; Viganò, M, 2018) |
"Tenofovir alafenamide (TAF) has recently been approved for chronic hepatitis B (CHB)." | 4.95 | Tenofovir alafenamide as compared to tenofovir disoproxil fumarate in the management of chronic hepatitis B with recent trends in patient demographics. ( Hsu, YC; Nguyen, MH; Wei, MT, 2017) |
"Renal anemia was induced by treatment with adenine (200 or 600 mg/kg/day, orally for 10 days) in non-diabetic Wistar-Kyoto or Wistar rats, respectively." | 3.96 | Failure to confirm a sodium-glucose cotransporter 2 inhibitor-induced hematopoietic effect in non-diabetic rats with renal anemia. ( Hitomi, H; Kittikulsuth, W; Kobara, H; Konishi, Y; Masaki, T; Morikawa, T; Nakano, D; Nishiyama, A; Osafune, K; Yamazaki, D, 2020) |
"Previous studies have demonstrated that the treatment of chronic hepatitis B (CHB) infection with adefovir (ADV) can impair renal function." | 3.80 | Telbivudine protects renal function in patients with chronic hepatitis B infection in conjunction with adefovir-based combination therapy. ( Kim, HY; Kim, YJ; Lee, HJ; Lee, HS; Lee, JH; Lee, M; Oh, S; Yeum, TS; Yoon, JH; Yu, SJ, 2014) |
"To investigate the effect of long-term tenofovir disoproxil fumarate (TDF) use on renal function, especially in patients with low body weight who are vulnerable to TDF nephrotoxicity." | 3.80 | Long-term exposure to tenofovir continuously decrease renal function in HIV-1-infected patients with low body weight: results from 10 years of follow-up. ( Aoki, T; Gatanaga, H; Honda, H; Kawasaki, Y; Kikuchi, Y; Kinai, E; Mizushima, D; Nishijima, T; Oka, S; Tanaka, N; Tanuma, J; Teruya, K; Tsukada, K; Watanabe, K; Yazaki, H, 2014) |
"Nephrogenic systemic fibrosis (NSF) is a scleroderma-like disease associated with prior administration of certain gadolinium chelates (GCs)." | 3.79 | Nephrogenic systemic fibrosis-like effects of magnetic resonance imaging contrast agents in rats with adenine-induced renal failure. ( Bouzian, N; Bruneval, P; Corot, C; Daubiné, F; Factor, C; Fretellier, N; Hollenbeck, C; Idée, JM; Jestin, G; Laprévote, O; Mandet, C; Massicot, F; Parmentier, N; Port, M, 2013) |
" We also found that co-infection with HCV and treatment by the antiretrovirat drug Tenofovir are significantly associated with the decline in renal function among our patients [p=0." | 3.79 | [Crucial risk factors for renal function deterioration of HIV-infected patients at the AIDS Clinic in Rambam Hospital]. ( Hassoun, G; Kedem, E; Mugrabi, F; Pollack, S; Shahar, E, 2013) |
"Adefovir and tenofovir are nucleotide analogues used as long-term therapy of chronic hepatitis B." | 3.78 | Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B. ( Chong, WH; Collins, MT; Gara, N; Ghany, MG; Hoofnagle, JH; Jake Liang, T; Kleiner, DE; Zhao, X, 2012) |
" Factors associated with elevated cystatin C included hepatitis C coinfection, hypertension, current smoking, older age, current tenofovir use, detectable plasma HIV RNA, and elevated microalbuminuria." | 3.78 | Cystatin C and baseline renal function among HIV-infected persons in the SUN Study. ( Brooks, JT; Bush, T; Conley, L; Hammer, J; Henry, K; Kojic, EM; Mondy, K; Overton, ET; Patel, P; Rhame, F, 2012) |
"This was a retrospective study of human immunodeficiency virus (HIV)-infected patients at a university-affiliated HIV clinic who were prescribed tenofovir between July 1, 2001, and January 31, 2009." | 3.77 | A comparison of tenofovir-associated renal function changes in HIV-infected African Americans vs Caucasians. ( Cocohoba, J; Gruta, C; John, MD; Lao, CK, 2011) |
"The study evaluated whether a liquid suspension of adefovir dipivoxil (ADV) is effective and safe when dose adjusted based on varying degrees of renal impairment in patients with chronic hepatitis B." | 3.77 | Efficacy and pharmacokinetics of adefovir dipivoxil liquid suspension in patients with chronic hepatitis B and renal impairment. ( Frederick, D; Pol, S; Rostaing, L; Rousseau, F; Schiff, E; Shiffman, ML; Thabut, D; Zeuzem, S; Zong, J, 2011) |
"Combination therapy with adefovir dipivoxil (ADV) and lamivudine (LAM) is recommended for patients infected with LAM-refractory hepatitis B virus (HBV)." | 3.76 | Add-on combination therapy with adefovir dipivoxil induces renal impairment in patients with lamivudine-refractory hepatitis B virus. ( Enomoto, M; Habu, D; Imanishi, Y; Iwai, S; Kawada, N; Kobayashi, S; Morikawa, H; Sakaguchi, H; Shiomi, S; Tamori, A, 2010) |
" A 40-year-old liver transplant recipient with hepatitis B virus reinfection, resistance to lamivudine, and fibrosing cholestatic hepatitis complicated by terminal renal impairment and spontaneous bacterial peritonitis was treated with adefovir dipivoxil 10 mg after every dialysis." | 3.72 | Successful treatment of fibrosing cholestatic hepatitis using adefovir dipivoxil in a patient with cirrhosis and renal insufficiency. ( Barg-Hock, H; Becker, T; Bleck, JS; Bock, CT; Böker, KH; Flemming, P; Klempnauer, J; Manns, MP; Rosenau, J; Tillmann, HL; Trautwein, C, 2003) |
"The adenine-containing diet caused renal failure, characterized by crystal deposits, cystic dilatation of tubules, and micro-abscesses." | 3.01 | Functional and histological effects of Anthurium schlechtendalii Kunth extracts on adenine-induced kidney damage of adult Wistar rats. ( Ajibola, OO; Barradas-Dermitz, DM; Calderón-Garcidueñas, AL; Carvajal-Zarrabal, O; López-Amador, N; Nolasco-Hipolito, C, 2023) |
" Although no dosage adjustment is needed for Oral Nirmatrelvir/Ritonavir in patients with mild renal impairment and coronavirus disease 2019, the dosage is reduced to twice daily in those with moderate renal impairment." | 3.01 | Medication safety in chronic kidney disease. ( Singh, S, 2023) |
"As expected for a renally eliminated drug, subjects with and without hepatic impairment displayed similar tenofovir systemic exposures without evidence of substantial alterations in drug disposition, and therefore no dosage adjustments were warranted in these patients." | 2.72 | Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment. ( Flaherty, JF; Kearney, BP; Shah, J; Yale, K; Zhong, L, 2006) |
"We pooled clinical renal safety data across 26 treatment-naive and antiretroviral switch studies to compare the incidence of proximal renal tubulopathy and discontinuation due to renal adverse events between participants taking TAF-containing regimens vs." | 2.61 | Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials. ( Arribas, JR; Brainard, D; Carter, C; Clarke, AE; Das, M; Elion, RA; Eron, JJ; Esser, S; Guo, S; Gupta, SK; Martin, H; Mudrikova, T; Negredo, E; Orkin, C; Podzamczer, D; Post, FA; Pozniak, AL; Rockstroh, JK; Sax, PE; SenGupta, D; Stellbrink, HJ; Waters, L; Wohl, DA; Zhong, L, 2019) |
" The most common drugs given with tenofovir were ritonavir or lopinavir-ritonavir (21 of 27 patients), atazanavir (5 of 27 patients), and didanosine (9 of 27 patients)." | 2.43 | Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. ( Bedford, J; Braden, G; Hoffman, R; Morris, A; Pizzoferrato, T; Zimmermann, AE, 2006) |
" Intracellular activation of a small fraction (< 10%) of the dose by cellular kinases leads to prolonged antiviral effects that are not easily predicted from conventional pharmacokinetic studies." | 2.40 | Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. ( Cundy, KC, 1999) |
"Kidney failure was induced chemically with an adenine-rich diet (0." | 1.72 | Polyphenol-rich açaí seed extract exhibits reno-protective and anti-fibrotic activities in renal tubular cells and mice with kidney failure. ( Borges, NA; Daleprane, JB; de Castro Resende, Â; Monteiro, EB; Monteiro, M; Soulage, CO, 2022) |
"Renal failure was induced by adding 0." | 1.62 | Safety and Gadolinium Distribution of the New High-Relaxivity Gadolinium Chelate Gadopiclenol in a Rat Model of Severe Renal Failure. ( Bocanegra, J; Corot, C; Factor, C; Fretellier, N; Idée, JM; Rasschaert, M; Robert, P; Seron, A, 2021) |
"Limited published real-world data describe adverse events (AEs) among patients treated for mantle-cell lymphoma (MCL)." | 1.62 | Adverse Events and Economic Burden Among Patients Receiving Systemic Treatment for Mantle Cell Lymphoma: A Real-World Retrospective Cohort Study. ( Byfield, SD; Kabadi, SM; LE, L; Olufade, T, 2021) |
"Fanconi syndrome with osteomalacia can develop in patients with chronic hepatitis B infection being treated with adefovir at a conventional low dosage of 10 mg/day." | 1.56 | Osteomalacia and renal failure due to Fanconi syndrome caused by long-term low-dose Adefovir Dipivoxil: a case report. ( Cen, X; Cui, Y; Liu, Z; Mu, G; Xiang, Q; Xie, Q; Yu, Y; Zhang, H; Zhang, J, 2020) |
"A reversible acute renal failure with no proximal tubulopathy and neuropsychiatric issues are discussed." | 1.51 | Overdose of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in an HIV-1-infected subject with attempted suicide. ( Álvarez, H; Díaz-Cambre, H; García-González, J; Llibre, JM; Mariño, A; Valcarce, N, 2019) |
"Renal failure was assessed by plasma and urinary markers." | 1.43 | The renal mitochondrial dysfunction in patients with vascular calcification is prevented by sodium thiosulfate. ( Krishnaraj, P; Kurian, GA; Ravindran, S, 2016) |
"Adenine-treated animals experienced weight-loss, polyuria and polydipsia; however, these effects were significantly attenuated in adenine-treated Gunn rats." | 1.42 | Endogenously elevated bilirubin modulates kidney function and protects from circulating oxidative stress in a rat model of adenine-induced kidney failure. ( Benzie, IF; Boon, AC; Briskey, D; Bulmer, AC; Coombes, JS; Fassett, RG; Gopalan, V; Lam, AK, 2015) |
"HIV-infected women (n = 101) on tenofovir-based therapy underwent intensive 24-h pharmacokinetic sampling." | 1.40 | Common clinical conditions - age, low BMI, ritonavir use, mild renal impairment - affect tenofovir pharmacokinetics in a large cohort of HIV-infected women. ( Anastos, K; Bacchetti, P; Baxi, SM; Cohen, M; Gandhi, M; Gange, SJ; Greenblatt, RM; Huang, Y; Minkoff, H; Scherzer, R; Shlipak, MG; Young, M, 2014) |
"New insights into the treatment of chronic hepatitis B with relevance for clinical practice have been adopted in these concise, revised guidelines." | 1.38 | The 2012 revised Dutch national guidelines for the treatment of chronic hepatitis B virus infection. ( Baak, BC; Bakker, CM; Beuers, UH; Brouwer, JT; Buster, EH; Drenth, JP; Honkoop, P; Janssen, HL; Kerbert-Dreteler, MJ; Koek, GH; Tan, AC; van der Spek, BW; van Erpecum, KJ; van Hoek, B; van Nieuwkerk, KM; van Soest, H; Vrolijk, JM, 2012) |
"Overall, the incidence of acute renal failure was 0." | 1.37 | Renal impairment in HIV-1 infected patients receiving antiretroviral regimens including tenofovir in a resource-limited setting. ( Chimsuntorn, S; Manosuthi, W; Nilkamhang, S; Prasithsirikul, W; Sungkanuparph, S; Tantanathip, P, 2011) |
"Npt2b(+/+) mice with adenine-induced renal failure had hyperphosphatemia and high plasma creatinine levels." | 1.37 | Inorganic phosphate homeostasis in sodium-dependent phosphate cotransporter Npt2b⁺/⁻ mice. ( Aranami, F; Fukushima, N; Furutani, J; Hanabusa, E; Horiba, N; Jishage, K; Kakefuda, M; Kaneko, I; Kawase, Y; Kido, S; Kuwahara, S; Matsumoto, K; Miyamoto, K; Mukai, T; Ohi, A; Ohtomo, S; Oikawa, Y; Sasaki, S; Segawa, H; Tachibe, T; Tateishi, H; Tatsumi, S; Tominaga, R; Ueda, O; Wada, NA, 2011) |
" Renal biopsy revealed toxic acute tubular necrosis, with distinctive proximal tubular eosinophilic inclusions representing giant mitochondria visible by light microscopy." | 1.36 | Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities. ( D'Agati, VD; Herlitz, LC; Markowitz, GS; Mohan, S; Radhakrishnan, J; Stokes, MB, 2010) |
"Rats with renal failure induced by an adenine diet exhibited severe abnormality of Ca dynamics, including Ca shortage and ectopic accumulation of Ca." | 1.36 | Systemic disorders of calcium dynamics in rats with adenine-induced renal failure: implication for chronic kidney disease-related complications. ( Ikeda, R; Imai, Y; Maruyama, W; Mizoguchi, K, 2010) |
"In this study, we present a case of renal failure in a patient who was on a tenofovir-containing regimen, resulting in extremely high tenofovir exposure and prolonged tenofovir monotherapy." | 1.35 | Prolonged exposure to tenofovir monotherapy 1 month after treatment discontinuation because of tenofovir-related renal failure. ( Beijnen, JH; Huitema, AD; Jansen, RS; Mulder, JW; Smits, PH; Ter Heine, R; van Gorp, EC; Wagenaar, JF, 2009) |
"Renal failure is associated with aortic valve calcification (AVC)." | 1.35 | Uraemic hyperparathyroidism causes a reversible inflammatory process of aortic valve calcification in rats. ( Abedat, S; Beeri, R; Ben-Dov, IZ; Danenberg, HD; Lotan, C; Meir, K; Planer, D; Shuvy, M; Sosna, J, 2008) |
"We report a biopsy-proven case of acute renal failure that developed within weeks of initiating a HAART regimen containing tenofovir, and review the literature with specific attention to cases of renal failure occurring within 8 weeks of tenofovir initiation." | 1.34 | Early onset of tenofovir-induced renal failure: case report and review of the literature. ( Ahya, SN; Kanwar, YS; Palella, F; Patel, SM; Zembower, TR, 2007) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (1.09) | 18.7374 |
1990's | 5 (5.43) | 18.2507 |
2000's | 25 (27.17) | 29.6817 |
2010's | 49 (53.26) | 24.3611 |
2020's | 12 (13.04) | 2.80 |
Authors | Studies |
---|---|
Ho, HJ | 1 |
Kikuchi, K | 1 |
Oikawa, D | 1 |
Watanabe, S | 1 |
Kanemitsu, Y | 1 |
Saigusa, D | 1 |
Kujirai, R | 1 |
Ikeda-Ohtsubo, W | 1 |
Ichijo, M | 1 |
Akiyama, Y | 1 |
Aoki, Y | 1 |
Mishima, E | 1 |
Ogata, Y | 1 |
Oikawa, Y | 2 |
Matsuhashi, T | 1 |
Toyohara, T | 1 |
Suzuki, C | 1 |
Suzuki, T | 1 |
Mano, N | 1 |
Kagawa, Y | 1 |
Owada, Y | 1 |
Katayama, T | 1 |
Nakayama, T | 1 |
Tomioka, Y | 1 |
Abe, T | 1 |
Sato, H | 3 |
Goto, M | 3 |
Nishimura, G | 3 |
Morimoto, N | 3 |
Tokushima, H | 3 |
Horii, Y | 3 |
Takahashi, N | 4 |
Monteiro, EB | 3 |
Borges, NA | 3 |
Monteiro, M | 3 |
de Castro Resende, Â | 3 |
Daleprane, JB | 3 |
Soulage, CO | 3 |
Singh, S | 1 |
Calderón-Garcidueñas, AL | 1 |
Barradas-Dermitz, DM | 1 |
Nolasco-Hipolito, C | 1 |
López-Amador, N | 1 |
Ajibola, OO | 1 |
Carvajal-Zarrabal, O | 1 |
Shuvy, M | 3 |
Abedat, S | 3 |
Eliaz, R | 1 |
Abu-Rmeileh, I | 1 |
Abu-Snieneh, A | 1 |
Ben-Dov, IZ | 2 |
Meir, K | 2 |
Pereg, D | 1 |
Beeri, R | 3 |
Lotan, C | 3 |
Yamazaki, D | 1 |
Konishi, Y | 1 |
Morikawa, T | 1 |
Kobara, H | 1 |
Masaki, T | 1 |
Hitomi, H | 1 |
Osafune, K | 1 |
Nakano, D | 1 |
Kittikulsuth, W | 1 |
Nishiyama, A | 1 |
Lampertico, P | 2 |
Buti, M | 1 |
Fung, S | 1 |
Ahn, SH | 1 |
Chuang, WL | 1 |
Tak, WY | 1 |
Ramji, A | 1 |
Chen, CY | 1 |
Tam, E | 1 |
Bae, H | 1 |
Ma, X | 1 |
Flaherty, JF | 2 |
Gaggar, A | 1 |
Lau, A | 1 |
Liu, Y | 2 |
Wu, G | 1 |
Suri, V | 1 |
Tan, SK | 1 |
Subramanian, GM | 1 |
Trinh, H | 1 |
Yoon, SK | 1 |
Agarwal, K | 1 |
Lim, YS | 1 |
Chan, HLY | 1 |
Xiang, Q | 1 |
Liu, Z | 2 |
Yu, Y | 1 |
Zhang, H | 1 |
Xie, Q | 1 |
Mu, G | 1 |
Zhang, J | 1 |
Cen, X | 1 |
Cui, Y | 1 |
Awad, AM | 1 |
Saleh, MA | 1 |
Abu-Elsaad, NM | 1 |
Ibrahim, TM | 1 |
Kumakura, S | 1 |
Sato, E | 1 |
Sekimoto, A | 1 |
Hashizume, Y | 1 |
Yamakage, S | 1 |
Miyazaki, M | 1 |
Ito, S | 1 |
Harigae, H | 1 |
Kabadi, SM | 1 |
Byfield, SD | 1 |
LE, L | 1 |
Olufade, T | 1 |
Fretellier, N | 2 |
Rasschaert, M | 1 |
Bocanegra, J | 1 |
Robert, P | 1 |
Factor, C | 2 |
Seron, A | 1 |
Idée, JM | 2 |
Corot, C | 2 |
Hsu, YC | 1 |
Wei, MT | 1 |
Nguyen, MH | 1 |
Viganò, M | 1 |
Loglio, A | 1 |
Grossi, G | 1 |
Álvarez, H | 1 |
Mariño, A | 1 |
Valcarce, N | 1 |
García-González, J | 1 |
Díaz-Cambre, H | 1 |
Llibre, JM | 1 |
Lv, Y | 1 |
Li, X | 1 |
Liang, S | 1 |
Liang, D | 1 |
Xu, F | 1 |
Zhu, X | 1 |
Zeng, C | 1 |
Gupta, SK | 2 |
Post, FA | 2 |
Arribas, JR | 1 |
Eron, JJ | 1 |
Wohl, DA | 1 |
Clarke, AE | 1 |
Sax, PE | 1 |
Stellbrink, HJ | 1 |
Esser, S | 1 |
Pozniak, AL | 1 |
Podzamczer, D | 1 |
Waters, L | 1 |
Orkin, C | 1 |
Rockstroh, JK | 1 |
Mudrikova, T | 1 |
Negredo, E | 1 |
Elion, RA | 1 |
Guo, S | 1 |
Zhong, L | 2 |
Carter, C | 1 |
Martin, H | 1 |
Brainard, D | 1 |
SenGupta, D | 1 |
Das, M | 1 |
Shahar, E | 1 |
Mugrabi, F | 1 |
Kedem, E | 1 |
Hassoun, G | 1 |
Pollack, S | 1 |
Tourret, J | 1 |
Deray, G | 1 |
Isnard-Bagnis, C | 1 |
Wu, M | 1 |
Tang, RN | 1 |
Liu, H | 1 |
Xu, M | 1 |
Pan, MM | 1 |
Liu, BC | 1 |
Baxi, SM | 1 |
Greenblatt, RM | 1 |
Bacchetti, P | 1 |
Scherzer, R | 1 |
Minkoff, H | 1 |
Huang, Y | 1 |
Anastos, K | 1 |
Cohen, M | 1 |
Gange, SJ | 1 |
Young, M | 1 |
Shlipak, MG | 1 |
Gandhi, M | 1 |
Mi, D | 1 |
Moe, SM | 1 |
Dubé, MP | 1 |
Lee, M | 1 |
Oh, S | 1 |
Lee, HJ | 1 |
Yeum, TS | 1 |
Lee, JH | 1 |
Yu, SJ | 1 |
Kim, HY | 1 |
Yoon, JH | 1 |
Lee, HS | 1 |
Kim, YJ | 1 |
Mulenga, L | 2 |
Musonda, P | 1 |
Mwango, A | 1 |
Vinikoor, MJ | 2 |
Davies, MA | 1 |
Mweemba, A | 2 |
Calmy, A | 1 |
Stringer, JS | 1 |
Keiser, O | 1 |
Chi, BH | 2 |
Wandeler, G | 2 |
Estrella, MM | 1 |
Moosa, MR | 1 |
Nachega, JB | 1 |
Zanolini, A | 1 |
Emge, D | 1 |
Nishijima, T | 2 |
Kawasaki, Y | 2 |
Tanaka, N | 2 |
Mizushima, D | 1 |
Aoki, T | 1 |
Watanabe, K | 1 |
Kinai, E | 1 |
Honda, H | 1 |
Yazaki, H | 1 |
Tanuma, J | 1 |
Tsukada, K | 1 |
Teruya, K | 1 |
Kikuchi, Y | 1 |
Gatanaga, H | 2 |
Oka, S | 2 |
Kamkuemah, M | 1 |
Kaplan, R | 1 |
Bekker, LG | 1 |
Little, F | 1 |
Myer, L | 1 |
Winston, J | 1 |
Andrade-Villanueva, JF | 1 |
Fisher, M | 1 |
Beraud, C | 1 |
Abram, ME | 1 |
Graham, H | 1 |
Rhee, MS | 1 |
Cheng, AK | 1 |
Szwarcberg, J | 1 |
Rokx, C | 1 |
Van der Ende, ME | 1 |
Rijnders, BJ | 1 |
Ueno, K | 1 |
Shimizu, M | 1 |
Kubo, T | 1 |
Igarashi, N | 1 |
Hatasaki, K | 1 |
Aguiar, CF | 1 |
Naffah-de-Souza, C | 1 |
Castoldi, A | 1 |
Corrêa-Costa, M | 1 |
Braga, TT | 1 |
Naka, ÉL | 1 |
Amano, MT | 1 |
Abate, DT | 1 |
Hiyane, MI | 1 |
Cenedeze, MA | 1 |
Pacheco e Silva Filho, A | 1 |
Câmara, NO | 1 |
Boon, AC | 1 |
Lam, AK | 1 |
Gopalan, V | 1 |
Benzie, IF | 1 |
Briskey, D | 1 |
Coombes, JS | 1 |
Fassett, RG | 1 |
Bulmer, AC | 1 |
Peng, YH | 1 |
Sweet, DH | 1 |
Lin, SP | 1 |
Yu, CP | 1 |
Lee Chao, PD | 1 |
Hou, YC | 1 |
Krishnaraj, P | 1 |
Ravindran, S | 1 |
Kurian, GA | 1 |
Wood, SM | 1 |
Shah, SS | 1 |
Steenhoff, AP | 1 |
Meyers, KE | 1 |
Kaplan, BS | 1 |
Rutstein, RM | 1 |
Matsui, I | 1 |
Hamano, T | 1 |
Mikami, S | 1 |
Fujii, N | 1 |
Takabatake, Y | 1 |
Nagasawa, Y | 1 |
Kawada, N | 2 |
Ito, T | 1 |
Rakugi, H | 1 |
Imai, E | 1 |
Isaka, Y | 1 |
Rodríguez-Nóvoa, S | 1 |
Labarga, P | 1 |
Soriano, V | 1 |
Egan, D | 1 |
Albalater, M | 1 |
Morello, J | 1 |
Cuenca, L | 1 |
González-Pardo, G | 1 |
Khoo, S | 1 |
Back, D | 1 |
Owen, A | 1 |
Ter Heine, R | 1 |
Huitema, AD | 1 |
Jansen, RS | 1 |
Smits, PH | 1 |
van Gorp, EC | 1 |
Wagenaar, JF | 1 |
Beijnen, JH | 1 |
Mulder, JW | 1 |
Tamori, A | 1 |
Enomoto, M | 1 |
Kobayashi, S | 1 |
Iwai, S | 1 |
Morikawa, H | 1 |
Sakaguchi, H | 1 |
Habu, D | 1 |
Shiomi, S | 1 |
Imanishi, Y | 1 |
O'Neill, WC | 1 |
Déti, EK | 1 |
Thiébaut, R | 1 |
Bonnet, F | 1 |
Lawson-Ayayi, S | 1 |
Dupon, M | 1 |
Neau, D | 1 |
Pellegrin, JL | 1 |
Malvy, D | 1 |
Tchamgoué, S | 1 |
Dabis, F | 1 |
Morlat, P | 1 |
Nyska, A | 1 |
Gal-Moscovici, A | 1 |
Rajamannan, NM | 1 |
Ikeda, R | 1 |
Imai, Y | 1 |
Maruyama, W | 1 |
Mizoguchi, K | 1 |
Ali, BH | 1 |
Al-Salam, S | 1 |
Al Husseni, I | 1 |
Kayed, RR | 1 |
Al-Masroori, N | 1 |
Al-Harthi, T | 1 |
Al Zaabi, M | 1 |
Nemmar, A | 1 |
Herlitz, LC | 1 |
Mohan, S | 1 |
Stokes, MB | 1 |
Radhakrishnan, J | 1 |
D'Agati, VD | 1 |
Markowitz, GS | 1 |
De Beaudrap, P | 1 |
Diallo, MB | 1 |
Landman, R | 1 |
Guèye, NF | 1 |
Ndiaye, I | 1 |
Diouf, A | 1 |
Kane, CT | 1 |
Etard, JF | 1 |
Girard, PM | 2 |
Sow, PS | 1 |
Delaporte, E | 1 |
Shiffman, ML | 1 |
Pol, S | 2 |
Rostaing, L | 1 |
Schiff, E | 1 |
Thabut, D | 1 |
Zeuzem, S | 1 |
Zong, J | 1 |
Frederick, D | 1 |
Rousseau, F | 1 |
Thurairajah, P | 1 |
Khanna, A | 1 |
Mutimer, D | 1 |
Chaisiri, K | 1 |
Bowonwatanuwong, C | 1 |
Kasettratat, N | 1 |
Kiertiburanakul, S | 1 |
Perazella, MA | 2 |
Xu, Z | 1 |
Chen, LB | 1 |
Cao, H | 1 |
Shu, X | 1 |
Xu, QH | 1 |
Li, G | 1 |
Xie, QF | 1 |
O'Donnell, EP | 1 |
Scarsi, KK | 1 |
Darin, KM | 1 |
Gerzenshtein, L | 1 |
Postelnick, MJ | 1 |
Palella, FJ | 1 |
Overton, ET | 1 |
Patel, P | 1 |
Mondy, K | 1 |
Bush, T | 1 |
Conley, L | 1 |
Rhame, F | 1 |
Kojic, EM | 1 |
Hammer, J | 1 |
Henry, K | 1 |
Brooks, JT | 1 |
Brennan, A | 1 |
Evans, D | 1 |
Maskew, M | 1 |
Naicker, S | 1 |
Ive, P | 1 |
Sanne, I | 1 |
Maotoe, T | 1 |
Fox, M | 1 |
Manosuthi, W | 1 |
Prasithsirikul, W | 1 |
Tantanathip, P | 1 |
Chimsuntorn, S | 1 |
Nilkamhang, S | 1 |
Sungkanuparph, S | 1 |
Ohi, A | 1 |
Hanabusa, E | 1 |
Ueda, O | 1 |
Segawa, H | 1 |
Horiba, N | 1 |
Kaneko, I | 1 |
Kuwahara, S | 1 |
Mukai, T | 1 |
Sasaki, S | 1 |
Tominaga, R | 1 |
Furutani, J | 1 |
Aranami, F | 1 |
Ohtomo, S | 1 |
Kawase, Y | 1 |
Wada, NA | 1 |
Tachibe, T | 1 |
Kakefuda, M | 1 |
Tateishi, H | 1 |
Matsumoto, K | 1 |
Tatsumi, S | 1 |
Kido, S | 1 |
Fukushima, N | 1 |
Jishage, K | 1 |
Miyamoto, K | 1 |
Lao, CK | 1 |
Gruta, C | 1 |
John, MD | 1 |
Cocohoba, J | 1 |
Gara, N | 1 |
Zhao, X | 1 |
Collins, MT | 1 |
Chong, WH | 1 |
Kleiner, DE | 1 |
Jake Liang, T | 1 |
Ghany, MG | 1 |
Hoofnagle, JH | 1 |
Johnson, DC | 1 |
Chasela, C | 1 |
Maliwichi, M | 1 |
Mwafongo, A | 1 |
Akinkuotu, A | 1 |
Moses, A | 1 |
Jamieson, DJ | 1 |
Kourtis, AP | 1 |
King, CC | 1 |
van der Horst, C | 1 |
Hosseinipour, MC | 1 |
Bouzian, N | 1 |
Parmentier, N | 1 |
Bruneval, P | 1 |
Jestin, G | 1 |
Mandet, C | 1 |
Daubiné, F | 1 |
Massicot, F | 1 |
Laprévote, O | 1 |
Hollenbeck, C | 1 |
Port, M | 1 |
Buster, EH | 1 |
Baak, BC | 1 |
Bakker, CM | 1 |
Beuers, UH | 1 |
Brouwer, JT | 1 |
Drenth, JP | 1 |
van Erpecum, KJ | 1 |
van Hoek, B | 1 |
Honkoop, P | 1 |
Kerbert-Dreteler, MJ | 1 |
Koek, GH | 1 |
van Nieuwkerk, KM | 1 |
van Soest, H | 1 |
van der Spek, BW | 1 |
Tan, AC | 1 |
Vrolijk, JM | 1 |
Janssen, HL | 1 |
Manolakopoulos, S | 1 |
Striki, A | 1 |
Papatheodoridis, GV | 1 |
Shimohata, H | 1 |
Sakai, S | 1 |
Ogawa, Y | 1 |
Hirayama, K | 1 |
Kobayashi, M | 1 |
Yokozawa, T | 3 |
Muto, Y | 1 |
Wakaki, K | 1 |
Kashiwagi, H | 1 |
Verhelst, D | 1 |
Monge, M | 1 |
Meynard, JL | 1 |
Fouqueray, B | 1 |
Mougenot, B | 1 |
Ronco, P | 1 |
Rossert, J | 1 |
Tillmann, HL | 1 |
Bock, CT | 1 |
Bleck, JS | 1 |
Rosenau, J | 1 |
Böker, KH | 1 |
Barg-Hock, H | 1 |
Becker, T | 1 |
Trautwein, C | 1 |
Klempnauer, J | 1 |
Flemming, P | 1 |
Manns, MP | 1 |
Karras, A | 1 |
Lafaurie, M | 1 |
Furco, A | 1 |
Bourgarit, A | 1 |
Droz, D | 1 |
Sereni, D | 1 |
Legendre, C | 1 |
Martinez, F | 1 |
Molina, JM | 1 |
JAHRMAERKER, H | 1 |
Rifkin, BS | 1 |
Jones, R | 1 |
Stebbing, J | 1 |
Nelson, M | 1 |
Moyle, G | 1 |
Bower, M | 1 |
Mandalia, S | 1 |
Gazzard, B | 1 |
Arnadottir, M | 1 |
Laxdal, T | 1 |
Halldorsdottir, B | 1 |
Fine, DM | 1 |
Fontaine, H | 1 |
Vallet-Pichard, A | 1 |
Chaix, ML | 1 |
Currie, G | 1 |
Serpaggi, J | 1 |
Verkarre, V | 1 |
Varaut, A | 1 |
Morales, E | 1 |
Nalpas, B | 1 |
Brosgart, C | 1 |
Zimmermann, AE | 1 |
Pizzoferrato, T | 1 |
Bedford, J | 1 |
Morris, A | 1 |
Hoffman, R | 1 |
Braden, G | 1 |
Kearney, BP | 1 |
Yale, K | 1 |
Shah, J | 1 |
Imaoka, T | 1 |
Kusuhara, H | 1 |
Adachi, M | 1 |
Schuetz, JD | 1 |
Takeuchi, K | 1 |
Sugiyama, Y | 1 |
Di Pietro, V | 1 |
Perruzza, I | 1 |
Amorini, AM | 1 |
Balducci, A | 1 |
Ceccarelli, L | 1 |
Lazzarino, G | 1 |
Barsotti, P | 1 |
Giardina, B | 1 |
Tavazzi, B | 1 |
Ray, AS | 1 |
Cihlar, T | 1 |
Patel, SM | 1 |
Zembower, TR | 1 |
Palella, F | 1 |
Kanwar, YS | 1 |
Ahya, SN | 1 |
Hamada, Y | 1 |
Kono, TN | 1 |
Moriguchi, Y | 1 |
Higuchi, M | 1 |
Fukagawa, M | 1 |
Danenberg, HD | 1 |
Planer, D | 1 |
Sosna, J | 1 |
Manouvrier, S | 1 |
Rötig, A | 1 |
Hannebique, G | 1 |
Gheerbrandt, JD | 1 |
Royer-Legrain, G | 1 |
Munnich, A | 1 |
Parent, M | 1 |
Grünfeld, JP | 1 |
Largilliere, C | 1 |
Lombes, A | 1 |
Lee, TW | 1 |
Oura, H | 2 |
Nonaka, G | 1 |
Nishioka, I | 1 |
Hattori, M | 1 |
Barrett, RJ | 1 |
Dong, E | 1 |
Cundy, KC | 1 |
Fukuwatari, T | 1 |
Morikawa, Y | 1 |
Hayakawa, F | 1 |
Sugimoto, E | 1 |
Shibata, K | 1 |
Lu, X | 1 |
Zhou, A | 1 |
Jin, C | 1 |
Bendele, RA | 1 |
Richardson, FC | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Switching From Tenofovir Disoproxil Fumarate (TDF) 300 mg QD to Tenofovir Alafenamide (TAF) 25 mg QD in Subjects With Chronic Hepatitis B Who Are Virologically Suppressed[NCT02979613] | Phase 3 | 490 participants (Actual) | Interventional | 2016-12-29 | Completed | ||
A Prospective Cohort Study of Tenofovir Alafenamide Switching Therapy in Kidney or Liver Transplant Recipients With Chronic Hepatitis B Virus Infection[NCT05410496] | Phase 4 | 50 participants (Anticipated) | Interventional | 2021-06-22 | Recruiting | ||
A Phase 3b, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Infected Subjects Who Are Virologically Suppressed on Regimens Containing ABC/3TC[NCT02469246] | Phase 3 | 567 participants (Actual) | Interventional | 2015-06-29 | Completed | ||
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults[NCT02607956] | Phase 3 | 657 participants (Actual) | Interventional | 2015-11-11 | Completed | ||
A Phase 3, Open-Label Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Combination Single Tablet Regimen (STR) in Virologically-Suppressed, HIV-1 Positive Subjects[NCT01815736] | Phase 3 | 1,443 participants (Actual) | Interventional | 2013-03-27 | Completed | ||
Effects of Sofosbuvir/Ledipasvir Treatment on the Pharmacokinetics and Renal Safety of Tenofovir[NCT02588287] | 14 participants (Actual) | Interventional | 2015-11-30 | Completed | |||
Effects of Ledipasvir/Sofosbuvir Treatment on the Pharmacokinetics and Renal Safety of Tenofovir Alafenamide (TAF) in Patients With HIV.[NCT03126370] | Phase 4 | 10 participants (Actual) | Interventional | 2018-01-08 | Completed | ||
CALVIH: Determination of Kidney Stone Risk Factors in Patients Infected With HIV[NCT02457494] | 23 participants (Actual) | Observational | 2015-05-31 | Completed | |||
Changes in Weight After Switch to Dolutegravir/Lamivudine or Doravirine/Tenofovir/Lamivudine Compared to Continued Treatment With Dolutegravir/Tenofovir/Lamivudine for Virologically Suppressed HIV Infection. AVERTAS-2[NCT04903847] | Phase 4 | 126 participants (Anticipated) | Interventional | 2021-02-02 | Recruiting | ||
A Phase 3 Open-label Safety Study of Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment[NCT01363011] | Phase 3 | 106 participants (Actual) | Interventional | 2011-05-31 | Completed | ||
The Effects of Vitamin D and Calcium Supplementation to Parathyroid Hormone in CHB Patients Treated With Tenofovir Disoproxil Fumarate[NCT05313477] | Phase 4 | 64 participants (Anticipated) | Interventional | 2022-05-01 | Recruiting | ||
Study to Understand the Natural History of HIV/AIDS in the Era of Effective Therapy (SUN Study)[NCT00146419] | 699 participants (Actual) | Observational | 2004-03-31 | Completed | |||
Open Label Study of Nucleus(t)Ide Treated Patients Randomised to Tenofovir, or Tenofovir + Telbivudine[NCT02774837] | Phase 4 | 146 participants (Actual) | Interventional | 2016-04-30 | Active, not recruiting | ||
Impact of Drug Therapy and Co-Morbidities on the Development of Renal Impairment in HIV-Infected Patients[NCT00551655] | 684 participants (Actual) | Observational | 2007-05-31 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
"Cockcroft-Gault formula is as follows:~For men: Glomerular filtration rate (GFR) = (140 - age in years) * body weight in kg / 72 * serum creatinine (mg/dL)~For women: GFR = 0.85 * (140 - age in years) * body weight in kg / 72 * serum creatinine (mg/dL).~Change from baseline was calculated as the value at Week 96 minus the value at Baseline." (NCT02979613)
Timeframe: Baseline; Week 96
Intervention | mL/min (Median) |
---|---|
TAF 25 mg | 1.626 |
TDF 300 mg | 0.544 |
"Cockcroft-Gault formula is as follows:~For men: Glomerular filtration rate (GFR) = (140 - age in years) * body weight in kg / 72 * serum creatinine (mg/dL)~For women: GFR = 0.85 * (140 - age in years) * body weight in kg / 72 * serum creatinine (mg/dL).~Change from baseline was calculated as the value at Week 48 minus the value at Baseline." (NCT02979613)
Timeframe: Baseline; Week 48
Intervention | mL/min (Median) |
---|---|
TAF 25 mg | 2.240 |
TDF 300 mg | -1.722 |
The FibroTest score is used to assess liver fibrosis. Scores range from 0.00 to 1.00, with higher scores indicating a greater degree of fibrosis. Change from baseline was calculated as the value at Week 48 minus the value at Baseline. (NCT02979613)
Timeframe: Baseline; Week 48
Intervention | scores on a scale (Mean) |
---|---|
TAF 25 mg | -0.02 |
TDF 300 mg | -0.01 |
The FibroTest score is used to assess liver fibrosis. Scores range from 0.00 to 1.00, with higher scores indicating a greater degree of fibrosis. Change from baseline was calculated as the value at Week 96 minus the value at Baseline. (NCT02979613)
Timeframe: Baseline; Week 96
Intervention | scores on a scale (Mean) |
---|---|
TAF 25 mg | -0.03 |
TDF 300 mg | -0.03 |
Percent Change = Change from baseline at a postbaseline visit/baseline * 100%. (NCT02979613)
Timeframe: Baseline; Week 96
Intervention | percent change (Mean) |
---|---|
TAF 25 mg | 1.157 |
TDF 300 mg | 0.180 |
Percent Change = Change from baseline at a postbaseline visit/baseline * 100%. (NCT02979613)
Timeframe: Baseline; Week 48
Intervention | percent change (Mean) |
---|---|
TAF 25 mg | 0.659 |
TDF 300 mg | -0.507 |
Percent Change = Change from baseline at a postbaseline visit/baseline * 100%. (NCT02979613)
Timeframe: Baseline; Week 48
Intervention | percent change (Mean) |
---|---|
TAF 25 mg | 1.743 |
TDF 300 mg | -0.138 |
Percent Change = Change from baseline at a postbaseline visit/baseline * 100%. (NCT02979613)
Timeframe: Baseline; Week 96
Intervention | percent change (Mean) |
---|---|
TAF 25 mg | 2.330 |
TDF 300 mg | 1.726 |
HBeAg loss was defined as HBeAg changing from positive at baseline to negative at a postbaseline visit with baseline HBeAb negative or missing. The M = F approach was used for this analysis. (NCT02979613)
Timeframe: Week 96
Intervention | percentage of participants (Number) |
---|---|
TAF 25 mg | 17.9 |
TDF 300 mg | 9.0 |
HBeAg seroconversion was defined as HBeAg loss and HBeAb changing from negative/missing at baseline to positive at a postbaseline visit. The M = F approach was used for this analysis. (NCT02979613)
Timeframe: Week 48
Intervention | percentage of participants (Number) |
---|---|
TAF 25 mg | 2.6 |
TDF 300 mg | 0.0 |
HBeAg seroconversion was defined as HBeAg loss and HBeAb changing from negative/missing at baseline to positive at a postbaseline visit. The M = F approach was used for this analysis. (NCT02979613)
Timeframe: Week 96
Intervention | percentage of participants (Number) |
---|---|
TAF 25 mg | 5.1 |
TDF 300 mg | 2.6 |
HBsAg loss was defined as HBsAg changing from positive at baseline to negative at a postbaseline visit with baseline HBsAb negative or missing. The M = F approach was used for this analysis. (NCT02979613)
Timeframe: Week 96
Intervention | percentage of participants (Number) |
---|---|
TAF 25 mg | 1.6 |
TDF 300 mg | 2.4 |
HBsAg seroconversion was defined as HBsAg loss and HBsAb changes from negative/missing at baseline to positive at a postbaseline visit. The M = F approach was used for this analysis. (NCT02979613)
Timeframe: Week 48
Intervention | percentage of participants (Number) |
---|---|
TAF 25 mg | 0.0 |
TDF 300 mg | 0.0 |
HBsAg seroconversion was defined as HBsAg loss and HBsAb changes from negative/missing at baseline to positive at a postbaseline visit. The M = F approach was used for this analysis. (NCT02979613)
Timeframe: Week 96
Intervention | percentage of participants (Number) |
---|---|
TAF 25 mg | 0.8 |
TDF 300 mg | 0.4 |
The percentage of participants with HBV DNA < 20 IU/mL at Week 48 was analyzed, which included participants who have the last available on-treatment HBV DNA, 20 IU/mL in the Week 48 analysis window. Missing=Failure (M = F) approach was used for analysis. (NCT02979613)
Timeframe: Weeks 48
Intervention | percentage of participants (Number) |
---|---|
TAF 25 mg | 96.3 |
TDF 300 mg | 96.3 |
The percentage of participants with HBV DNA < 20 IU/mL at Week 96 was analyzed, which included participants who have the last available on-treatment HBV DNA, 20 IU/mL in the Week 96 analysis window. M = F approach was used for analysis. (NCT02979613)
Timeframe: Week 96
Intervention | percentage of participants (Number) |
---|---|
TAF 25 mg | 94.7 |
TDF 300 mg | 93.9 |
"The percentage of participants with HBV DNA ≥ 20 IU/mL at Week 96 was analyzed using the modified US FDA-defined snapshot algorithm, which included participants who:~Had the last available on-treatment HBV DNA ≥ 20 IU/mL in the Week 96 analysis window (from Day 589 to Day 840, inclusive), or~Did not have on-treatment HBV DNA data available in the Week 96 analysis window and~Discontinued study drug prior to or in the Week 96 analysis window due to lack of efficacy, or~Discontinued study drug prior to or in the Week 96 analysis window due to reason other than lack of efficacy and had the last available on-treatment HBV DNA ≥ 20 IU/mL" (NCT02979613)
Timeframe: Week 96
Intervention | percentage of participants (Number) |
---|---|
TAF 25 mg | 0.4 |
TDF 300 mg | 0.4 |
HBeAg loss was defined as HBeAg changing from positive at baseline to negative at a postbaseline visit with baseline HBeAb negative or missing. The M = F approach was used for this analysis. (NCT02979613)
Timeframe: Week 48
Intervention | percentage of participants (Number) |
---|---|
TAF 25 mg | 7.7 |
TDF 300 mg | 6.4 |
HBsAg loss was defined as HBsAg changing from positive at baseline to negative at a postbaseline visit with baseline HBsAb negative or missing. The M = F approach was used for this analysis. (NCT02979613)
Timeframe: Week 48
Intervention | percentage of participants (Number) |
---|---|
TAF 25 mg | 0.0 |
TDF 300 mg | 2.0 |
"The percentage of participants with HBV DNA ≥ 20 IU/mL at Week 48 was analyzed using the modified US FDA-defined snapshot algorithm, which included participants who:~Had the last available on-treatment HBV DNA ≥ 20 IU/mL in the Week 48 analysis window (from Day 295 to Day 378, inclusive), or~Did not have on-treatment HBV DNA data available in the Week 48 analysis window and~Discontinued study drug prior to or in the Week 48 analysis window due to lack of efficacy, or~Discontinued study drug prior to or in the Week 48 analysis window due to reason other than lack of efficacy and had the last available on-treatment HBV DNA ≥ 20 IU/mL" (NCT02979613)
Timeframe: Week 48
Intervention | percentage of participants (Number) |
---|---|
TAF 25 mg | 0.4 |
TDF 300 mg | 0.4 |
The percentage of participants with HBV DNA < 20 IU/mL at Week 48 was analyzed, which included participants who have the last available on-treatment HBV DNA, 20 IU/mL in the Week 48 analysis window. The method of determining percentage of participants with HBV DNA levels <20 IU/mL (target detected/not detected i.e., lower limit of detection) at Week 48, was handled by M = F, and Missing=Excluded (M = E) approaches. (NCT02979613)
Timeframe: Week 48
Intervention | percentage of participants (Number) | |||
---|---|---|---|---|
M = F Approach: < 20 IU/mL Target Not Detected | M = F Approach: < 20 IU/mL Target Detected | M = E Approach: < 20 IU/mL Target Not Detected | M = E Approach: < 20 IU/mL Target Detected | |
TAF 25 mg | 63.4 | 32.9 | 65.5 | 34.0 |
TDF 300 mg | 62.0 | 34.3 | 64.1 | 35.4 |
The percentage of participants with HBV DNA < 20 IU/mL at Week 96 was analyzed, which included participants who have the last available on-treatment HBV DNA, 20 IU/mL in the Week 96 analysis window. The method of determining percentage of participants with HBV DNA levels <20 IU/mL (target detected/not detected i.e., lower limit of detection) at Week 96, was handled by Missing=Failure (M = F), and Missing=Excluded (M = E) approaches. (NCT02979613)
Timeframe: Week 96
Intervention | percentage of participants (Number) | |||
---|---|---|---|---|
M = F Approach: < 20 IU/mL Target Not Detected | M = F Approach: < 20 IU/mL Target Detected | M = E Approach: < 20 IU/mL Target Not Detected | M = E Approach: < 20 IU/mL Target Detected | |
TAF 25 mg | 65.8 | 28.8 | 69.3 | 30.3 |
TDF 300 mg | 66.1 | 27.8 | 70.1 | 29.4 |
Central laboratory ULN for ALT were as follows: ≤ 43 U/L for males aged 18 to < 69 years and ≤ 35 U/L for males aged ≥ 69 years; ≤ 34 U/L for females aged 18 to < 69 years and ≤ 32 U/L for females aged ≥ 69 years. The ULN for ALT using the 2018 AASLD normal range was 25 U/L for females and 35 U/L for males. M = F approach was used for analysis. (NCT02979613)
Timeframe: Week 48
Intervention | percentage of participants (Number) | |
---|---|---|
Central Laboratory Criteria | AASLD Criteria | |
TAF 25 mg | 89.3 | 79.0 |
TDF 300 mg | 84.9 | 75.1 |
Central laboratory ULN for ALT were as follows: ≤ 43 U/L for males aged 18 to < 69 years and ≤ 35 U/L for males aged ≥ 69 years; ≤ 34 U/L for females aged 18 to < 69 years and ≤ 32 U/L for females aged ≥ 69 years. The ULN for ALT using the 2018 AASLD normal range was 25 U/L for females and 35 U/L for males. M = F approach was used for analysis. (NCT02979613)
Timeframe: Week 96
Intervention | percentage of participants (Number) | |
---|---|---|
Central Laboratory Criteria | AASLD Criteria | |
TAF 25 mg | 88.5 | 80.7 |
TDF 300 mg | 91.4 | 86.5 |
ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit. Central laboratory ULN for ALT were as follows: ≤ 43 U/L for males aged 18 to < 69 years and ≤ 35 U/L for males aged ≥ 69 years; ≤ 34 U/L for females aged 18 to < 69 years and ≤ 32 U/L for females aged ≥ 69 years. The ULN for ALT using the 2018 AASLD normal range was 25 U/L for females and 35 U/L for males. M = F approach was used for analysis. (NCT02979613)
Timeframe: Week 48
Intervention | percentage of participants (Number) | |
---|---|---|
Central Laboratory Criteria | AASLD Criteria | |
TAF 25 mg | 50.0 | 50.0 |
TDF 300 mg | 36.8 | 26.4 |
ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit. Central laboratory ULN for ALT were as follows: ≤ 43 U/L for males aged 18 to < 69 years and ≤ 35 U/L for males aged ≥ 69 years; ≤ 34 U/L for females aged 18 to < 69 years and ≤ 32 U/L for females aged ≥ 69 years. The ULN for ALT using the 2018 AASLD normal range was 25 U/L for females and 35 U/L for males. M = F approach was used for analysis. (NCT02979613)
Timeframe: Week 96
Intervention | percentage of participants (Number) | |
---|---|---|
Central Laboratory Criteria | AASLD Criteria | |
TAF 25 mg | 56.3 | 55.8 |
TDF 300 mg | 78.9 | 73.6 |
(NCT02469246)
Timeframe: Baseline; Week 48
Intervention | cells/µL (Mean) |
---|---|
F/TAF | -30 |
ABC/3TC | 2 |
(NCT02469246)
Timeframe: Baseline; Week 96
Intervention | cells/μL (Mean) |
---|---|
F/TAF | -29 |
ABC/3TC | 10 |
(NCT02469246)
Timeframe: Baseline; Week 96
Intervention | percent change (Mean) |
---|---|
F/TAF | 0.169 |
ABC/3TC | 0.021 |
(NCT02469246)
Timeframe: Baseline; Week 48
Intervention | percent change (Mean) |
---|---|
F/TAF | 0.246 |
ABC/3TC | 0.086 |
(NCT02469246)
Timeframe: Baseline; Week 48
Intervention | percent change (Mean) |
---|---|
F/TAF | 0.081 |
ABC/3TC | -0.052 |
(NCT02469246)
Timeframe: Baseline; Week 96
Intervention | percent change (Mean) |
---|---|
F/TAF | 0.178 |
ABC/3TC | 0.235 |
The percentage of participants achieving HIV-1 RNA < 20 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02469246)
Timeframe: Week 48
Intervention | percentage of participants (Number) |
---|---|
F/TAF | 85.7 |
ABC/3TC | 87.3 |
The percentage of participants achieving HIV-1 RNA < 20 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02469246)
Timeframe: Week 96
Intervention | percentage of participants (Number) |
---|---|
F/TAF | 80.4 |
ABC/3TC | 86.2 |
The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02469246)
Timeframe: Week 48
Intervention | percentage of participants (Number) |
---|---|
F/TAF | 88.6 |
ABC/3TC | 92.4 |
The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02469246)
Timeframe: Week 96
Intervention | percentage of participants (Number) |
---|---|
F/TAF | 82.1 |
ABC/3TC | 88.4 |
The percentage of participants with HIV-1 RNA ≥ 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02469246)
Timeframe: Week 48
Intervention | percentage of participants (Number) |
---|---|
F/TAF | 1.8 |
ABC/3TC | 0.7 |
The percentage of participants with HIV-1 RNA ≥ 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02469246)
Timeframe: Week 96
Intervention | percentage of participants (Number) |
---|---|
F/TAF | 2.5 |
ABC/3TC | 1.1 |
(NCT02607956)
Timeframe: Baseline, Week 144
Intervention | cells/μL (Mean) |
---|---|
B/F/TAF | 278 |
DTG + F/TAF | 289 |
(NCT02607956)
Timeframe: Baseline, Week 48
Intervention | cells/μL (Mean) |
---|---|
B/F/TAF | 180 |
DTG + F/TAF | 201 |
(NCT02607956)
Timeframe: Baseline, open-label Week 48
Intervention | cells/μL (Mean) |
---|---|
All B/F/TAF | 304 |
DTG + F/TAF to B/F/TAF | 9 |
(NCT02607956)
Timeframe: Baseline, Week 96
Intervention | cells/μL (Mean) |
---|---|
B/F/TAF | 237 |
DTG + F/TAF | 281 |
(NCT02607956)
Timeframe: Baseline, open-label Week 96
Intervention | cells/µL (Mean) |
---|---|
All B/F/TAF | 336 |
DTG + F/TAF to B/F/TAF | -10 |
(NCT02607956)
Timeframe: Baseline, Week 144
Intervention | log10 copies/mL (Mean) |
---|---|
B/F/TAF | -3.06 |
DTG + F/TAF | -3.11 |
(NCT02607956)
Timeframe: Baseline, Week 48
Intervention | log10 copies/mL (Mean) |
---|---|
B/F/TAF | -3.07 |
DTG + F/TAF | -3.12 |
(NCT02607956)
Timeframe: Baseline, Week 96
Intervention | log10 copies/mL (Mean) |
---|---|
B/F/TAF | -3.08 |
DTG + F/TAF | -3.10 |
The percentage of participants achieving HIV-1 RNA < 20 copies/mL at Week 144 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02607956)
Timeframe: Week 144
Intervention | percentage of participants (Number) |
---|---|
B/F/TAF | 77.5 |
DTG + F/TAF | 79.1 |
The percentage of participants achieving HIV-1 RNA < 20 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02607956)
Timeframe: Week 48
Intervention | percentage of participants (Number) |
---|---|
B/F/TAF | 82.2 |
DTG + F/TAF | 87.1 |
The percentage of participants achieving HIV-1 RNA < 20 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02607956)
Timeframe: Week 96
Intervention | percentage of participants (Number) |
---|---|
B/F/TAF | 77.5 |
DTG + F/TAF | 80.3 |
The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 144 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02607956)
Timeframe: Week 144
Intervention | percentage of participants (Number) |
---|---|
B/F/TAF | 81.9 |
DTG + F/TAF | 84.0 |
The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02607956)
Timeframe: Week 48
Intervention | percentage of participants (Number) |
---|---|
B/F/TAF | 89.4 |
DTG + F/TAF | 92.9 |
The percentage of participants with HIV-1 RNA < 50 copies/mL was analyzed using Missing = Excluded for imputing missing HIV-1 RNA values using the All B/F/TAF Analysis Set for the all B/F/TAF analysis. All missing data was excluded in the computation of the percentages (ie, missing data points were excluded from both the numerator and denominator in the computation). The denominator for percentages at a visit was the number of participants in the all B/F/TAF analysis set with nonmissing HIV-1 RNA value at that visit. (NCT02607956)
Timeframe: Baseline, open-label Week 48
Intervention | percentage of participants (Number) |
---|---|
All B/F/TAF | 99.2 |
DTG + F/TAF to B/F/TAF | 99.6 |
The percentage of participants with HIV-1 RNA < 50 copies/mL was analyzed using Missing = Failure for imputing missing HIV-1 RNA values using the All B/F/TAF Analysis Set for the all B/F/TAF analysis. All missing data was treated as HIV-1 RNA ≥ 50 copies/mL. The denominator for percentages was the number of participants in all B/F/TAF analysis set. (NCT02607956)
Timeframe: Baseline, open-label Week 48
Intervention | percentage of participants (Number) |
---|---|
All B/F/TAF | 75.3 |
DTG + F/TAF to B/F/TAF | 84.5 |
The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02607956)
Timeframe: Week 96
Intervention | percentage of participants (Number) |
---|---|
B/F/TAF | 84.1 |
DTG + F/TAF | 86.5 |
The percentage of participants with HIV-1 RNA < 50 copies/mL was analyzed using Missing = Excluded for imputing missing HIV-1 RNA values using the All B/F/TAF Analysis Set for the all B/F/TAF analysis. All missing data was excluded in the computation of the percentages (ie, missing data points were excluded from both the numerator and denominator in the computation). The denominator for percentages at a visit was the number of participants in the all B/F/TAF analysis set with nonmissing HIV-1 RNA value at that visit. (NCT02607956)
Timeframe: Baseline, open-label Week 96
Intervention | percentage of participants (Number) |
---|---|
All B/F/TAF | 99.5 |
DTG + F/TAF to B/F/TAF | 99.1 |
The percentage of participants with HIV-1 RNA < 50 copies/mL was analyzed using Missing = Failure for imputing missing HIV-1 RNA values using the All B/F/TAF Analysis Set for the all B/F/TAF analysis. All missing data was treated as HIV-1 RNA ≥ 50 copies/mL. The denominator for percentages was the number of participants in all B/F/TAF analysis set. (NCT02607956)
Timeframe: Baseline, open-label Week 96
Intervention | percentage of participants (Number) |
---|---|
All B/F/TAF | 68.1 |
DTG + F/TAF to B/F/TAF | 87.5 |
The percentage of participants achieving HIV-1 RNA < 20 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01815736)
Timeframe: Week 96
Intervention | percentage of participants (Number) |
---|---|
E/C/F/TAF | 90.6 |
Stay on Baseline Treatment Regimen (SBR) | 85.3 |
The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01815736)
Timeframe: Week 96
Intervention | percentage of participants (Number) |
---|---|
E/C/F/TAF | 92.8 |
Stay on Baseline Treatment Regimen (SBR) | 89.1 |
The analysis of CD4 cell count included values up to 1 day after the last dose date of randomized study drug.The change from baseline in CD4 cell count for the full analysis set was based on observed data (ie, Missing = Excluded) for the total and by the prior treatment regimen. (NCT01815736)
Timeframe: Baseline; Week 96
Intervention | cells/uL (Mean) | |
---|---|---|
Baseline | Change at Week 96 | |
E/C/F/TAF | 701 | 60 |
Stay on Baseline Treatment Regimen (SBR) | 689 | 42 |
The analysis of CD4 cell count included values up to 1 day after the last dose date of randomized study drug.The change from baseline in CD4 cell count for the full analysis set was based on observed data (ie, Missing = Excluded) for the total and by the prior treatment regimen. (NCT01815736)
Timeframe: Baseline; Week 48
Intervention | cells/uL (Mean) | |||
---|---|---|---|---|
Baseline (NDA Data Cut) | Change at Week 48 (NDA Data Cut) | Baseline (All Participants) | Change at Week 48 (All Participants) | |
E/C/F/TAF | 712 | 33 | 701 | 35 |
Stay on Baseline Treatment Regimen (SBR) | 690 | 27 | 689 | 24 |
(NCT01815736)
Timeframe: Baseline; Week 48
Intervention | mg/dL (Mean) | |
---|---|---|
NDA Data Cut | All Participants | |
E/C/F/TAF | -0.01 | 0.00 |
Stay on Baseline Treatment Regimen (SBR) | 0.04 | 0.03 |
"The mean (SD) change of the overall EFV-related symptom assessment score is presented. The overall symptom score (ranging from 0 to 20) is the sum of the individual symptom scores ranging from 0 (no symptoms) to 4 (most severe symptoms) from the 5 EFV-related symptom assessments (dizziness, trouble sleeping, impaired concentration, sleepiness, and abnormal or vivid dream). A negative change from baseline indicates improvement.~EFV-Related Symptom Analysis Set: participants who received EFV/FTC/TDF as prior treatment, received at least 1 dose of study drug, and completed EFV-related symptom assessments at the baseline visit and at least 1 postbaseline visit." (NCT01815736)
Timeframe: Baseline; Week 48
Intervention | units on a scale (Mean) | |
---|---|---|
NDA Data Cut | All Participants | |
E/C/F/TAF | -1.6 | -1.5 |
Stay on Baseline Treatment Regimen (SBR) | -0.1 | -0.1 |
Hip BMD was assessed by dual energy x-ray absorptiometry (DXA) scan. BMD is calculated as grams per square centimeter (g/cm^2); the mean (SD) percentage change is presented. (NCT01815736)
Timeframe: Baseline; Week 48
Intervention | percentage change (Mean) | |
---|---|---|
NDA Data Cut | All Participants | |
E/C/F/TAF | 1.949 | 1.468 |
Stay on Baseline Treatment Regimen (SBR) | -0.136 | -0.340 |
Spine BMD was assessed by DXA scan. BMD is calculated as g/cm^2; the mean (SD) percentage change is presented. (NCT01815736)
Timeframe: Baseline; Week 48
Intervention | percentage change (Mean) | |
---|---|---|
NDA Data Cut | All Participants | |
E/C/F/TAF | 1.861 | 1.557 |
Stay on Baseline Treatment Regimen (SBR) | -0.110 | -0.443 |
The percentage of participants achieving HIV-1 RNA < 20 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01815736)
Timeframe: Week 48
Intervention | percentage of participants (Number) | |
---|---|---|
NDA Data Cut | All Participants | |
E/C/F/TAF | 92.2 | 93.5 |
Stay on Baseline Treatment Regimen (SBR) | 90.4 | 90.4 |
The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01815736)
Timeframe: Week 48
Intervention | percentage of participants (Number) | |
---|---|---|
NDA Data Cut | All Participants | |
E/C/F/TAF | 95.6 | 97.2 |
Stay on Baseline Treatment Regimen (SBR) | 92.9 | 93.1 |
Compare plasma tenofovir AUC0-24 between TAF with boosted PI vs. TDF with boosted PI (Phase 2 vs. 1), and between TAF with boosted PI and LDV/SOF vs. TDF with boosted PI (Phase 3 vs. 1) (NCT03126370)
Timeframe: 12 weeks and 24 weeks and 28 weeks
Intervention | ng*h/mL (Geometric Mean) |
---|---|
TDF With a Boosted PI | 3466 |
TAF With a Boosted PI | 743 |
TAF With a Boosted PI and LDV/SOF | 868 |
Compare tenofovir diphosphate (TFV-DP) in dried blood spots (DBS) between TAF with a boosted PI vs. TDF with a boosted PI (Phase 2 vs. 1), and TAF with a boosted PI and LDV/SOF vs. TDF with a boosted PI (Phase 3 vs. 1) (NCT03126370)
Timeframe: 12 weeks and 24 and 28 weeks
Intervention | fmol/2x7mm punches (Geometric Mean) |
---|---|
TDF With a Boosted PI | 36014 |
TAF With a Boosted PI | 6735 |
TAF With a Boosted PI and LDV/SOF | 6100 |
Compare tenofovir-diphosphate (TFV-DP) in peripheral blood mononuclear cells (PBMCs) between TAF with a boosted PI vs. TDF with a boosted PI (Phase 2 vs. 1), and TAF with a boosted PI and LDV/SOF vs. TDF with a boosted PI (Phase 3 vs. 1). (NCT03126370)
Timeframe: 12 weeks, and 24 weeks and 28 weeks
Intervention | fmol/10^6 cells (Geometric Mean) |
---|---|
TDF With a Boosted PI | 83.0 |
TAF With a Boosted PI | 926 |
TAF With a Boosted PI and LDV/SOF | 1129 |
Change in estimated glomerular filtration rate (eGFR) (NCT03126370)
Timeframe: 12 weeks, 24 weeks, and 28 weeks
Intervention | mL/min/1.73 m^2 (Geometric Mean) |
---|---|
TDF With a Boosted PI | 86.7 |
TAF With a Boosted PI | 91.0 |
TAF With a Boosted PI and LDV/SOF | 88.1 |
Change in estimated glomerular filtration rate (eGFR) and renal biomarkers: Urine protein to creatinine ratio (UPCR) (NCT03126370)
Timeframe: 12 weeks, 24 weeks, and 28 weeks
Intervention | mg/g (Geometric Mean) |
---|---|
TDF With a Boosted PI | 134 |
TAF With a Boosted PI | 118 |
TAF With a Boosted PI and LDV/SOF | 97.3 |
Change in renal biomarkers: urinary beta-2 microglobulin (B2M)/creatinine (Cr) ratio, and urinary retinol binding protein (RBP)/Cr ratio (NCT03126370)
Timeframe: 12 weeks, 24 weeks, and 28 weeks
Intervention | ug/g (Geometric Mean) | |
---|---|---|
β2M:Cr ratio | RBP:Cr ratio | |
TAF With a Boosted PI | 224 | 242 |
TAF With a Boosted PI and LDV/SOF | 178 | 146 |
TDF With a Boosted PI | 419 | 436 |
The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 24 was analyzed in Cohort 1 (treatment-naive) using the FDA snapshot analysis algorithm. (NCT01363011)
Timeframe: Week 24
Intervention | percentage of participants (Number) |
---|---|
E/C/F/TDF (Cohort 1) | 84.8 |
The percentage of participants with HIV-1 RNA < 50 copies/mL at Week 24 was analyzed in Cohort 2 (treatment-experienced) using the FDA snapshot analysis algorithm. (NCT01363011)
Timeframe: Week 24
Intervention | percentage of participants (Number) |
---|---|
COBI+PI+2 NRTIs (Cohort 2) | 90.4 |
Change from baseline in aGFR at Weeks 2, 4, and 24 was analyzed in Cohort 1 (treatment-naive). aGFR was calculated using iohexol plasma clearance. (NCT01363011)
Timeframe: Baseline; Weeks 2, 4, and 24
Intervention | mL/min (Number) | |||
---|---|---|---|---|
Baseline | Change at Week 2 | Change at Week 4 | Change at Week 24 | |
E/C/F/TDF (Cohort 1) | 81.6 | -12.1 | -7.3 | -3.3 |
Change from baseline in aGFR at Weeks 2, 4, and 24 was analyzed in Cohort 2 (treatment-experienced). aGFR was calculated using iohexol plasma clearance. (NCT01363011)
Timeframe: Baseline; Weeks 2, 4, and 24
Intervention | mL/min (Median) | |||
---|---|---|---|---|
Baseline | Change at Week 2 (n=13) | Change at Week 4 (n=13) | Change at Week 24 (n=11) | |
COBI+PI+2 NRTIs (Cohort 2) | 82.5 | 1.6 | 7.0 | -4.1 |
Change from baseline in eGFR-CKD-EPI based on cystatin C equation (not adjusted for age, sex, and race) at Week 24 was analyzed in Cohort 1 (treatment-naive). The calculation was normalized to 1.73 m^2 body surface area. (NCT01363011)
Timeframe: Baseline; Week 24
Intervention | mL/min/1.73 m^2 (Median) | |
---|---|---|
Baseline (n = 33) | Change at Week 24 (n = 30) | |
E/C/F/TDF (Cohort 1) | 77.6 | 0.3 |
Change from baseline in eGFR-MDRD equation at Week 24 was analyzed in Cohort 1 (treatment-naive). The calculation was normalized to 1.73 m^2 body surface area. (NCT01363011)
Timeframe: Baseline; Week 24
Intervention | mL/min/1.73 m^2 (Median) | |
---|---|---|
Baseline (n = 33) | Change at Week 24 (n = 30) | |
E/C/F/TDF (Cohort 1) | 77.1 | -7.4 |
Change from baseline in eGFR-CG equation at Week 24 was analyzed in Cohort 2 (treatment-experienced). (NCT01363011)
Timeframe: Baseline; Week 24
Intervention | mL/min (Median) | |
---|---|---|
Baseline (n = 73) | Change at Week 24 (n = 67) | |
COBI+PI+2 NRTIs (Cohort 2) | 71.4 | -3.7 |
Change from baseline in eGFR-CG at Weeks 48 and 96 were analyzed in Cohort 1 (treatment-naive). This outcome is to measure the long-term effect of COBI-containing regimens on renal parameters. (NCT01363011)
Timeframe: Baseline; Weeks 48 and 96
Intervention | mL/min (Median) | |
---|---|---|
Change at Week 48 (n = 28) | Change at Week 96 (n = 25) | |
E/C/F/TDF (Cohort 1) | -7.6 | -7.9 |
Change from baseline in eGFR-CG at Weeks 48 and 96 were analyzed in Cohort 2 (treatment-experienced). This outcome is to measure the long-term effect of COBI-containing regimens on renal parameters. (NCT01363011)
Timeframe: Baseline; Week 48
Intervention | mL/min (Median) | |
---|---|---|
Change at Week 48 (n = 63) | Change at Week 96 (n = 50) | |
COBI+PI+2 NRTIs (Cohort 2) | -3.8 | -5.0 |
Change from baseline in eGFR-CKD-EPI based on cystatin C equation (adjusted for age, sex, and race) at Weeks 48 and 96 were analyzed in Cohort 1 (treatment-naive). The calculation was normalized to 1.73 m^2 body surface area. This outcome is to measure the long-term effect of COBI-containing regimens on renal parameters. (NCT01363011)
Timeframe: Baseline; Weeks 48 and 96
Intervention | mL/min/1.73 m^2 (Median) | |
---|---|---|
Change at Week 48 (n = 28) | Change at Week 96 (n = 25) | |
E/C/F/TDF (Cohort 1) | 1.6 | 12.6 |
Change from baseline in eGFR-CKD-EPI based on cystatin C equation (adjusted for age, sex, and race) at Weeks 48 and 96 were analyzed in Cohort 2 (treatment-experienced). The calculation was normalized to 1.73 m^2 body surface area. This outcome is to measure the long-term effect of COBI-containing regimens on renal parameters. (NCT01363011)
Timeframe: Baseline; Weeks 48 and 96
Intervention | mL/min/1.73 m^2 (Median) | |
---|---|---|
Change at Week 48 (n = 63) | Change at Week 96 (n = 50) | |
COBI+PI+2 NRTIs (Cohort 2) | -4.7 | -2.8 |
Change from baseline in eGFR-CKD-EPI based on cystatin C equation (not adjusted for age, sex, and race) at Weeks 48 and 96 were analyzed in Cohort 1 (treatment-naive). The calculation was normalized to 1.73 m^2 body surface area. This outcome is to measure the long-term effect of COBI-containing regimens on renal parameters. (NCT01363011)
Timeframe: Baseline; Weeks 48 and 96
Intervention | mL/min/1.73 m^2 (Median) | |
---|---|---|
Change at Week 48 (n = 28) | Change at Week 96 (n = 25) | |
E/C/F/TDF (Cohort 1) | 1.9 | 12.4 |
Change from baseline in eGFR-CKD-EPI based on cystatin C equation (not adjusted for age, sex, and race) at Weeks 48 and 96 were analyzed in Cohort 2 (treatment-experienced). The calculation was normalized to 1.73 m^2 body surface area. This outcome is to measure the long-term effect of COBI-containing regimens on renal parameters. (NCT01363011)
Timeframe: Baseline; Weeks 48 and 96
Intervention | mL/min/1.73 m^2 (Median) | |
---|---|---|
Change at Week 48 (n = 63) | Change at Week 96 (n = 50) | |
COBI+PI+2 NRTIs (Cohort 2) | -4.7 | -2.4 |
Change from baseline in eGFR-CKD-EPI based on cystatin C equation (adjusted for age, sex, and race) at Week 24 was analyzed in Cohort 1 (treatment-naive). The calculation was normalized to 1.73 m^2 body surface area. (NCT01363011)
Timeframe: Baseline; Week 24
Intervention | mL/min/1.73 m^2 (Median) | |
---|---|---|
Baseline (n = 33) | Change at Week 24 (n = 30) | |
E/C/F/TDF (Cohort 1) | 76.9 | 0.3 |
Change from baseline in eGFR-CKD-EPI based on cystatin C equation (adjusted for age, sex, and race) at Week 24 was analyzed in Cohort 2 (treatment-experienced). The calculation was normalized to 1.73 m^2 body surface area. (NCT01363011)
Timeframe: Baseline; Week 24
Intervention | mL/min/1.73 m^2 (Median) | |
---|---|---|
Baseline (n = 73) | Change at Week 24 (n = 67) | |
COBI+PI+2 NRTIs (Cohort 2) | 78.2 | -2.8 |
Change from baseline in eGFR-CKD-EPI based on cystatin C equation (not adjusted for age, sex, and race) at Week 24 was analyzed in Cohort 2 (treatment-experienced). The calculation was normalized to 1.73 m^2 body surface area. (NCT01363011)
Timeframe: Baseline; Week 24
Intervention | mL/min/1.73 m^2 (Median) | |
---|---|---|
Baseline (n = 73) | Change at Week 24 (n = 67) | |
COBI+PI+2 NRTIs (Cohort 2) | 78.6 | -2.7 |
Change from baseline in eGFR-MDRD equation at Week 24 was analyzed in Cohort 2 (treatment-experienced). The calculation was normalized to 1.73 m^2 body surface area. (NCT01363011)
Timeframe: Baseline; Week 24
Intervention | mL/min/1.73 m^2 (Median) | |
---|---|---|
Baseline (n = 73) | Change at Week 24 (n = 67) | |
COBI+PI+2 NRTIs (Cohort 2) | 65.8 | -3.4 |
Change from baseline in eGFR-MDRD at Weeks 48 and 96 were analyzed in Cohort 1 (treatment-naive). The calculation was normalized to 1.73 m^2 body surface area. This outcome is to measure the long-term effect of COBI-containing regimens on renal parameters. (NCT01363011)
Timeframe: Baseline; Weeks 48 and 96
Intervention | mL/min/1.73 m^2 (Median) | |
---|---|---|
Change at Week 48 (n = 28) | Change at Week 96 (n = 25) | |
E/C/F/TDF (Cohort 1) | -12.1 | -12.9 |
Change from baseline in eGFR-MDRD at Weeks 48 and 96 were analyzed in Cohort 2 (treatment-experienced). The calculation was normalized to 1.73 m^2 body surface area. This outcome is to measure the long-term effect of COBI-containing regimens on renal parameters. (NCT01363011)
Timeframe: Baseline; Weeks 48 and 96
Intervention | mL/min/1.73 m^2 (Median) | |
---|---|---|
Change at Week 48 (n = 63) | Change at Week 96 (n = 50) | |
COBI+PI+2 NRTIs (Cohort 2) | -3.9 | -2.8 |
Change from baseline in eGFR-CG equation at Week 24 was analyzed in Cohort 1 (treatment-naive). (NCT01363011)
Timeframe: Baseline; Week 24
Intervention | mL/min (Median) | |
---|---|---|
Baseline (n = 33) | Change at Week 24 (n = 30) | |
E/C/F/TDF (Cohort 1) | 72.9 | -5.2 |
Adverse events (AEs) occurring from baseline up to 30 days following the last dose of study drug were summarized for Cohort 1 (treatment-naive). A participant was counted once if they had a qualifying event. (NCT01363011)
Timeframe: Up to 147 weeks plus 30 days
Intervention | percentage of participants (Number) | |||||
---|---|---|---|---|---|---|
Any AE | Drug-related AE | Grade 3 or higher AE | AE leading to drug discontinuation | Serious AE | AE of proximal renal tubulopathy | |
E/C/F/TDF (Cohort 1) | 100.0 | 48.5 | 21.2 | 12.1 | 18.2 | 0 |
Adverse events (AEs) occurring from baseline up to 30 days following the last dose of study drug were summarized for Cohort 2 (treatment-experienced). A participant was counted once if they had a qualifying event. (NCT01363011)
Timeframe: Up to 166 weeks plus 30 days
Intervention | percentage of participants (Number) | |||||
---|---|---|---|---|---|---|
Any AE | Drug-related AE | Grade 3 or higher AE | AE leading to drug discontinuation | Serious AE | AE of proximal renal tubulopathy | |
COBI+PI+2 NRTIs (Cohort 2) | 93.2 | 27.4 | 28.8 | 11.0 | 15.1 | 0 |
Laboratory abnormalities were summarized for Cohort 1 (treatment-naive) and were defined as values that increased at least one toxicity grade from baseline at any time postbaseline up to and including the date of last dose of study drug plus 30 days. A participant was counted once if they had a qualifying event. (NCT01363011)
Timeframe: Up to 147 weeks plus 30 days
Intervention | percentage of participants (Number) | |
---|---|---|
Any laboratory abnormality | Grade 3 or 4 laboratory abnormality | |
E/C/F/TDF (Cohort 1) | 100.0 | 39.4 |
Laboratory abnormalities were summarized for Cohort 2 (treatment-experienced) and were defined as values that increased at least one toxicity grade from baseline at any time postbaseline up to and including the date of last dose of study drug plus 30 days. A participant was counted once if they had a qualifying event. (NCT01363011)
Timeframe: Up to 166 weeks plus 30 days
Intervention | percentage of participants (Number) | |
---|---|---|
Any laboratory abnormality | Grade 3 or 4 laboratory abnormality | |
COBI+PI+2 NRTIs (Cohort 2) | 100.00 | 50.0 |
The percentage of participants with HIV-1 RNA < 50 copies/mL at Weeks 48 and 96 were analyzed in Cohort 1 (treatment-naive) using the FDA snapshot analysis algorithm. (NCT01363011)
Timeframe: Weeks 48 and 96
Intervention | percentage of participants (Number) | |
---|---|---|
Week 48 (n = 33) | Week 96 (n = 27) | |
E/C/F/TDF (Cohort 1) | 78.8 | 88.9 |
The percentage of participants with HIV-1 RNA < 50 copies/mL at Weeks 48 and 96 were analyzed in Cohort 2 (treatment-experienced) using the FDA snapshot analysis algorithm. (NCT01363011)
Timeframe: Weeks 48 and 96
Intervention | percentage of participants (Number) | |
---|---|---|
Week 48 (n = 73) | Week 96 (n = 54) | |
COBI+PI+2 NRTIs (Cohort 2) | 82.2 | 90.7 |
AUCtau was analyzed for Cohort 1 (treatment-naive) and was defined as the concentration of drug over time (area under the plasma concentration versus time curve over the dosing interval). (NCT01363011)
Timeframe: Blood samples were collected at 0 (predose), 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 8.0, 12.0, and 24.0 hours postdose at baseline and Weeks 2, 4, and 24.
Intervention | h*ng/mL (Number) | ||
---|---|---|---|
Week 2 | Week 4 | Week 24 | |
E/C/F/TDF (Cohort 1) | 16554.7 | 12704.1 | 9799.7 |
AUCtau was analyzed for Cohort 2 (treatment-experienced) and was defined as the concentration of drug over time (area under the plasma concentration versus time curve over the dosing interval). (NCT01363011)
Timeframe: Blood samples were collected at 0 (predose), 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 8.0, 12.0, and 24.0 hours postdose at baseline and Weeks 2, 4, and 24.
Intervention | h*ng/mL (Mean) | ||
---|---|---|---|
Week 2 (n = 13) | Week 4 (n = 13) | Week 24 (n = 11) | |
COBI+PI+2 NRTIs (Cohort 2) | 12458.0 | 11165.3 | 13980.5 |
Cmax was analyzed for Cohort 1 (treatment-naive) and was defined as the maximum observed concentration of drug in plasma. (NCT01363011)
Timeframe: Blood samples were collected at 0 (predose), 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 8.0, 12.0, and 24.0 hours postdose at baseline and Weeks 2, 4, and 24.
Intervention | ng/mL (Number) | ||
---|---|---|---|
Week 2 | Week 4 | Week 24 | |
E/C/F/TDF (Cohort 1) | 1734.6 | 1522.9 | 1266.4 |
Cmax was analyzed for Cohort 2 (treatment-experienced) and was defined as the maximum observed concentration of drug in plasma. (NCT01363011)
Timeframe: Blood samples were collected at 0 (predose), 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 8.0, 12.0, and 24.0 hours postdose at baseline and Weeks 2, 4, and 24.
Intervention | ng/mL (Mean) | ||
---|---|---|---|
Week 2 (n = 13) | Week 4 (n = 13) | Week 24 (n = 11) | |
COBI+PI+2 NRTIs (Cohort 2) | 1366.7 | 1297.7 | 1568.6 |
Ctau was analyzed for Cohort 1 (treatment-naive) and was defined as the observed drug concentration at the end of the dosing interval. (NCT01363011)
Timeframe: Blood samples were collected at 0 (predose), 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 8.0, 12.0, and 24.0 hours postdose at baseline and Weeks 2, 4, and 24.
Intervention | ng/mL (Number) | ||
---|---|---|---|
Week 2 | Week 4 | Week 24 | |
E/C/F/TDF (Cohort 1) | 150.5 | 37.3 | 24.2 |
Ctau was analyzed for Cohort 2 (treatment-experienced) and was defined as the observed drug concentration at the end of the dosing interval. (NCT01363011)
Timeframe: Blood samples were collected at 0 (predose), 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 8.0, 12.0, and 24.0 hours postdose at baseline and Weeks 2, 4, and 24.
Intervention | ng/mL (Mean) | ||
---|---|---|---|
Week 2 (n = 13) | Week 4 (n = 13) | Week 24 (n = 11) | |
COBI+PI+2 NRTIs (Cohort 2) | 79.9 | 71.3 | 139.8 |
t1/2 was analyzed for Cohort 1 (treatment-naive) and was defined as the estimate of the terminal elimination half-life of the drug. (NCT01363011)
Timeframe: Blood samples were collected at 0 (predose), 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 8.0, 12.0, and 24.0 hours postdose at baseline and Weeks 2, 4, and 24.
Intervention | hours (Number) | ||
---|---|---|---|
Week 2 | Week 4 | Week 24 | |
E/C/F/TDF (Cohort 1) | 6.14 | 3.57 | 3.63 |
t1/2 was analyzed for Cohort 2 (treatment-experienced) and was defined as the estimate of the terminal elimination half-life of the drug. (NCT01363011)
Timeframe: Blood samples were collected at 0 (predose), 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 8.0, 12.0, and 24.0 hours postdose at baseline and Weeks 2, 4, and 24.
Intervention | hours (Median) | ||
---|---|---|---|
Week 2 (n = 13) | Week 4 (n = 12) | Week 24 (n = 10) | |
COBI+PI+2 NRTIs (Cohort 2) | 4.37 | 3.98 | 3.77 |
Tmax was analyzed for Cohort 1 (treatment-naive) and was defined as the time of Cmax. (NCT01363011)
Timeframe: Blood samples were collected at 0 (predose), 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 8.0, 12.0, and 24.0 hours postdose at baseline and Weeks 2, 4, and 24.
Intervention | hours (Number) | ||
---|---|---|---|
Week 2 | Week 4 | Week 24 | |
E/C/F/TDF (Cohort 1) | 4.00 | 2.00 | 4.00 |
Tmax was analyzed for Cohort 2 (treatment-experienced) and was defined as the time of Cmax. (NCT01363011)
Timeframe: Blood samples were collected at 0 (predose), 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 8.0, 12.0, and 24.0 hours postdose at baseline and Weeks 2, 4, and 24.
Intervention | hours (Median) | ||
---|---|---|---|
Week 2 (n = 13) | Week 4 (n = 13) | Week 24 (n = 11) | |
COBI+PI+2 NRTIs (Cohort 2) | 3.92 | 4.92 | 3.00 |
11 reviews available for adenine and Kidney Failure
Article | Year |
---|---|
Medication safety in chronic kidney disease.
Topics: Adenine; COVID-19; Humans; Kidney; Renal Insufficiency; Renal Insufficiency, Chronic; Tenofovir | 2023 |
Functional and histological effects of Anthurium schlechtendalii Kunth extracts on adenine-induced kidney damage of adult Wistar rats.
Topics: Adenine; Adult; Animals; Araceae; Humans; Inflammation; Kidney; Kidney Diseases; Plant Extracts; Rat | 2023 |
Tenofovir alafenamide as compared to tenofovir disoproxil fumarate in the management of chronic hepatitis B with recent trends in patient demographics.
Topics: Adenine; Age Factors; Alanine; Antiviral Agents; Bone Density; Clinical Decision-Making; Female; Glo | 2017 |
Tenofovir alafenamide (TAF) treatment of HBV, what are the unanswered questions?
Topics: Adenine; Alanine; Antiviral Agents; Bone Density; Dose-Response Relationship, Drug; Hepatitis B, Chr | 2018 |
Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Anti-HIV Agents; Child; Female; Humans | 2019 |
Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Anti-HIV Agents; Child; Female; Humans | 2019 |
Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Anti-HIV Agents; Child; Female; Humans | 2019 |
Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Anti-HIV Agents; Child; Female; Humans | 2019 |
Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Anti-HIV Agents; Child; Female; Humans | 2019 |
Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Anti-HIV Agents; Child; Female; Humans | 2019 |
Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Anti-HIV Agents; Child; Female; Humans | 2019 |
Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Anti-HIV Agents; Child; Female; Humans | 2019 |
Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Anti-HIV Agents; Child; Female; Humans | 2019 |
Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword?
Topics: Adenine; Antirheumatic Agents; Clinical Trials as Topic; HIV Infections; Humans; Incidence; Kidney; | 2013 |
Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword?
Topics: Adenine; Antirheumatic Agents; Clinical Trials as Topic; HIV Infections; Humans; Incidence; Kidney; | 2013 |
Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword?
Topics: Adenine; Antirheumatic Agents; Clinical Trials as Topic; HIV Infections; Humans; Incidence; Kidney; | 2013 |
Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword?
Topics: Adenine; Antirheumatic Agents; Clinical Trials as Topic; HIV Infections; Humans; Incidence; Kidney; | 2013 |
Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword?
Topics: Adenine; Antirheumatic Agents; Clinical Trials as Topic; HIV Infections; Humans; Incidence; Kidney; | 2013 |
Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword?
Topics: Adenine; Antirheumatic Agents; Clinical Trials as Topic; HIV Infections; Humans; Incidence; Kidney; | 2013 |
Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword?
Topics: Adenine; Antirheumatic Agents; Clinical Trials as Topic; HIV Infections; Humans; Incidence; Kidney; | 2013 |
Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword?
Topics: Adenine; Antirheumatic Agents; Clinical Trials as Topic; HIV Infections; Humans; Incidence; Kidney; | 2013 |
Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword?
Topics: Adenine; Antirheumatic Agents; Clinical Trials as Topic; HIV Infections; Humans; Incidence; Kidney; | 2013 |
Tenofovir-associated nephrotoxicity in two HIV-infected adolescent males.
Topics: Adenine; Adolescent; Age Factors; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Black or A | 2009 |
Editorial comment: tenofovir nephrotoxicity--vigilance required.
Topics: Adenine; Fanconi Syndrome; Glycosuria; HIV Infections; Humans; Hypokalemia; Hypophosphatemia; Organo | 2005 |
Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions.
Topics: Adenine; Aged; Anti-HIV Agents; Creatinine; Drug Interactions; Humans; Male; Middle Aged; Organophos | 2006 |
Realizing the potential of adenosine-receptor-based therapeutics.
Topics: Adenine; Animals; Clinical Trials as Topic; Humans; Norbornanes; Pain; Purinergic P1 Receptor Agonis | 1996 |
Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir.
Topics: Adenine; Administration, Oral; Animals; Antiviral Agents; Cidofovir; Cytosine; Drug Interactions; Hu | 1999 |
6 trials available for adenine and Kidney Failure
Article | Year |
---|---|
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study.
Topics: Adenine; Alanine; Antiviral Agents; Bone Density; Creatinine; DNA, Viral; Double-Blind Method; Drug | 2020 |
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study.
Topics: Adenine; Alanine; Antiviral Agents; Bone Density; Creatinine; DNA, Viral; Double-Blind Method; Drug | 2020 |
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study.
Topics: Adenine; Alanine; Antiviral Agents; Bone Density; Creatinine; DNA, Viral; Double-Blind Method; Drug | 2020 |
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study.
Topics: Adenine; Alanine; Antiviral Agents; Bone Density; Creatinine; DNA, Viral; Double-Blind Method; Drug | 2020 |
Effects of switching from efavirenz to raltegravir on endothelial function, bone mineral metabolism, inflammation, and renal function: a randomized, controlled trial.
Topics: Adenine; Adult; Alkaline Phosphatase; Anti-HIV Agents; Biomarkers; Bone and Bones; C-Reactive Protei | 2013 |
[Efficacy of the 96-week adefovir dipivoxil therapy in patients with chronic hepatitis B].
Topics: Adenine; Adolescent; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Genotype; | 2010 |
Tenofovir use and renal insufficiency among pregnant and general adult population of HIV-infected, ART-naïve individuals in Lilongwe, Malawi.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Body Mass Index; CD4 Lymphocyte | 2012 |
Efficacy and safety of adefovir dipivoxil in kidney recipients, hemodialysis patients, and patients with renal insufficiency.
Topics: Adenine; Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis | 2005 |
Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment.
Topics: Adenine; Adult; Aged; Drug Administration Schedule; Drug Monitoring; Female; Humans; Liver Diseases; | 2006 |
75 other studies available for adenine and Kidney Failure
Article | Year |
---|---|
SGLT-1-specific inhibition ameliorates renal failure and alters the gut microbial community in mice with adenine-induced renal failure.
Topics: Adenine; Animals; Blood Glucose; Gastrointestinal Microbiome; Mice; Mice, Inbred C57BL; Renal Insuff | 2021 |
Upacicalcet, a positive allosteric modulator of the calcium-sensing receptor, prevents vascular calcification and bone disorder in a rat adenine-induced secondary hyperparathyroidism model.
Topics: Adenine; Animals; Bone Diseases; Calcium; Hyperparathyroidism, Secondary; Hyperplasia; Parathyroid H | 2023 |
Upacicalcet, a positive allosteric modulator of the calcium-sensing receptor, prevents vascular calcification and bone disorder in a rat adenine-induced secondary hyperparathyroidism model.
Topics: Adenine; Animals; Bone Diseases; Calcium; Hyperparathyroidism, Secondary; Hyperplasia; Parathyroid H | 2023 |
Upacicalcet, a positive allosteric modulator of the calcium-sensing receptor, prevents vascular calcification and bone disorder in a rat adenine-induced secondary hyperparathyroidism model.
Topics: Adenine; Animals; Bone Diseases; Calcium; Hyperparathyroidism, Secondary; Hyperplasia; Parathyroid H | 2023 |
Upacicalcet, a positive allosteric modulator of the calcium-sensing receptor, prevents vascular calcification and bone disorder in a rat adenine-induced secondary hyperparathyroidism model.
Topics: Adenine; Animals; Bone Diseases; Calcium; Hyperparathyroidism, Secondary; Hyperplasia; Parathyroid H | 2023 |
Upacicalcet, a positive allosteric modulator of the calcium-sensing receptor, prevents vascular calcification and bone disorder in a rat adenine-induced secondary hyperparathyroidism model.
Topics: Adenine; Animals; Bone Diseases; Calcium; Hyperparathyroidism, Secondary; Hyperplasia; Parathyroid H | 2023 |
Upacicalcet, a positive allosteric modulator of the calcium-sensing receptor, prevents vascular calcification and bone disorder in a rat adenine-induced secondary hyperparathyroidism model.
Topics: Adenine; Animals; Bone Diseases; Calcium; Hyperparathyroidism, Secondary; Hyperplasia; Parathyroid H | 2023 |
Upacicalcet, a positive allosteric modulator of the calcium-sensing receptor, prevents vascular calcification and bone disorder in a rat adenine-induced secondary hyperparathyroidism model.
Topics: Adenine; Animals; Bone Diseases; Calcium; Hyperparathyroidism, Secondary; Hyperplasia; Parathyroid H | 2023 |
Upacicalcet, a positive allosteric modulator of the calcium-sensing receptor, prevents vascular calcification and bone disorder in a rat adenine-induced secondary hyperparathyroidism model.
Topics: Adenine; Animals; Bone Diseases; Calcium; Hyperparathyroidism, Secondary; Hyperplasia; Parathyroid H | 2023 |
Upacicalcet, a positive allosteric modulator of the calcium-sensing receptor, prevents vascular calcification and bone disorder in a rat adenine-induced secondary hyperparathyroidism model.
Topics: Adenine; Animals; Bone Diseases; Calcium; Hyperparathyroidism, Secondary; Hyperplasia; Parathyroid H | 2023 |
Polyphenol-rich açaí seed extract exhibits reno-protective and anti-fibrotic activities in renal tubular cells and mice with kidney failure.
Topics: Adenine; Animals; Antioxidants; Fibrosis; Humans; Kidney; Male; Mice; Plant Extracts; Polyphenols; R | 2022 |
Polyphenol-rich açaí seed extract exhibits reno-protective and anti-fibrotic activities in renal tubular cells and mice with kidney failure.
Topics: Adenine; Animals; Antioxidants; Fibrosis; Humans; Kidney; Male; Mice; Plant Extracts; Polyphenols; R | 2022 |
Polyphenol-rich açaí seed extract exhibits reno-protective and anti-fibrotic activities in renal tubular cells and mice with kidney failure.
Topics: Adenine; Animals; Antioxidants; Fibrosis; Humans; Kidney; Male; Mice; Plant Extracts; Polyphenols; R | 2022 |
Polyphenol-rich açaí seed extract exhibits reno-protective and anti-fibrotic activities in renal tubular cells and mice with kidney failure.
Topics: Adenine; Animals; Antioxidants; Fibrosis; Humans; Kidney; Male; Mice; Plant Extracts; Polyphenols; R | 2022 |
Hyperphosphatemia is required for initiation but not propagation of kidney failure-induced calcific aortic valve disease.
Topics: Adenine; Animals; Aortic Valve; Calcinosis; Disease Progression; Extracellular Signal-Regulated MAP | 2019 |
Failure to confirm a sodium-glucose cotransporter 2 inhibitor-induced hematopoietic effect in non-diabetic rats with renal anemia.
Topics: Adenine; Anemia; Animals; Disease Models, Animal; Erythropoietin; Hematocrit; Hematopoietic Stem Cel | 2020 |
Osteomalacia and renal failure due to Fanconi syndrome caused by long-term low-dose Adefovir Dipivoxil: a case report.
Topics: Adenine; Antiviral Agents; Fanconi Syndrome; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organo | 2020 |
Erlotinib can halt adenine induced nephrotoxicity in mice through modulating ERK1/2, STAT3, p53 and apoptotic pathways.
Topics: Adenine; Animals; Disease Models, Animal; Fibrosis; Humans; Kidney; Kidney Diseases; MAP Kinase Sign | 2020 |
Nicotinamide Attenuates the Progression of Renal Failure in a Mouse Model of Adenine-Induced Chronic Kidney Disease.
Topics: Adenine; Animals; Citric Acid Cycle; Disease Models, Animal; Disease Progression; Energy Metabolism; | 2021 |
Adverse Events and Economic Burden Among Patients Receiving Systemic Treatment for Mantle Cell Lymphoma: A Real-World Retrospective Cohort Study.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydro | 2021 |
Safety and Gadolinium Distribution of the New High-Relaxivity Gadolinium Chelate Gadopiclenol in a Rat Model of Severe Renal Failure.
Topics: Adenine; Animals; Azabicyclo Compounds; Brain; Contrast Media; Gadolinium; Gadolinium DTPA; Organome | 2021 |
Overdose of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in an HIV-1-infected subject with attempted suicide.
Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Drug Combinations; Drug Overdose; Emtricitabine; HIV | 2019 |
The clinical and pathological features of adefovir dipivoxil-related renal impairment
.
Topics: Adenine; Adult; Antiviral Agents; Creatinine; Female; Glycosuria; Hematuria; Hepatitis B, Chronic; H | 2019 |
[Crucial risk factors for renal function deterioration of HIV-infected patients at the AIDS Clinic in Rambam Hospital].
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Coinfection; Female; Glomerular Filtration Rate; Hepatitis C; | 2013 |
Cinacalcet attenuates the renal endothelial-to-mesenchymal transition in rats with adenine-induced renal failure.
Topics: Adenine; Animals; Cell Differentiation; Cholesterol 7-alpha-Hydroxylase; Cinacalcet; Endothelial Cel | 2014 |
Common clinical conditions - age, low BMI, ritonavir use, mild renal impairment - affect tenofovir pharmacokinetics in a large cohort of HIV-infected women.
Topics: Adenine; Adult; Age Factors; Anti-HIV Agents; Body Mass Index; Cohort Studies; Female; Glomerular Fi | 2014 |
Telbivudine protects renal function in patients with chronic hepatitis B infection in conjunction with adefovir-based combination therapy.
Topics: Adenine; Adult; Aged; Antiviral Agents; DNA, Viral; Drug Therapy, Combination; Female; Glomerular Fi | 2014 |
Effect of baseline renal function on tenofovir-containing antiretroviral therapy outcomes in Zambia.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Creatinine; Female; Glomerul | 2014 |
Editorial commentary: Risks and benefits of tenofovir in the context of kidney dysfunction in sub-Saharan Africa.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; Glomerular Filtration Rate; | 2014 |
Chronic hepatitis B virus coinfection is associated with renal impairment among Zambian HIV-infected adults.
Topics: Adenine; Adolescent; Adult; Africa; Anti-HIV Agents; Coinfection; Female; Glomerular Filtration Rate | 2014 |
Long-term exposure to tenofovir continuously decrease renal function in HIV-1-infected patients with low body weight: results from 10 years of follow-up.
Topics: Adenine; Adult; Anti-HIV Agents; Body Weight; Cohort Studies; Female; Glomerular Filtration Rate; HI | 2014 |
Renal impairment in HIV-infected patients initiating tenofovir-containing antiretroviral therapy regimens in a Primary Healthcare Setting in South Africa.
Topics: Adenine; Adult; Age Factors; Anemia; Anti-HIV Agents; CD4 Lymphocyte Count; Female; Glomerular Filtr | 2015 |
Elvitegravir/cobicistat/emtricitabine/tenofovir DF in HIV-infected patients with mild-to-moderate renal impairment.
Topics: Adenine; Adult; Anti-HIV Agents; Carbamates; Cobicistat; Cohort Studies; Deoxycytidine; Emtricitabin | 2015 |
How does weight influence tenofovir disoproxil-fumarate induced renal function decline?
Topics: Adenine; Anti-HIV Agents; Body Weight; Female; Glomerular Filtration Rate; HIV Infections; Humans; M | 2015 |
Reply to 'how does weight influence tenofovir disoproxil-fumarate induced renal function decline?'.
Topics: Adenine; Anti-HIV Agents; Body Weight; Female; Glomerular Filtration Rate; HIV Infections; Humans; M | 2015 |
An infant with nephrolithiasis and renal failure: Answers.
Topics: Adenine; Adenine Phosphoribosyltransferase; Allopurinol; Humans; Infant; Kidney Calculi; Renal Insuf | 2016 |
Administration of α-Galactosylceramide Improves Adenine-Induced Renal Injury.
Topics: Adenine; Animals; Antigens, CD1d; Collagen Type I; Galactosylceramides; Hepatitis A Virus Cellular R | 2015 |
Endogenously elevated bilirubin modulates kidney function and protects from circulating oxidative stress in a rat model of adenine-induced kidney failure.
Topics: Adenine; Animals; Bilirubin; Kidney Function Tests; Oxidative Stress; Rats; Rats, Gunn; Rats, Wistar | 2015 |
Green tea inhibited the elimination of nephro-cardiovascular toxins and deteriorated the renal function in rats with renal failure.
Topics: Adenine; Animals; Catechin; CHO Cells; Creatinine; Cresols; Cricetinae; Cricetulus; Disease Models, | 2015 |
The renal mitochondrial dysfunction in patients with vascular calcification is prevented by sodium thiosulfate.
Topics: Adenine; Animals; Antioxidants; Aorta; Apoptosis; Catalase; DNA Fragmentation; Glutathione; Glutathi | 2016 |
Fully phosphorylated fetuin-A forms a mineral complex in the serum of rats with adenine-induced renal failure.
Topics: Adenine; Alendronate; alpha-Fetoproteins; Animals; Calcinosis; Chemical Precipitation; Liver; Male; | 2009 |
Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study.
Topics: Adenine; Adult; Anti-HIV Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette | 2009 |
Prolonged exposure to tenofovir monotherapy 1 month after treatment discontinuation because of tenofovir-related renal failure.
Topics: Adenine; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; HI | 2009 |
Add-on combination therapy with adefovir dipivoxil induces renal impairment in patients with lamivudine-refractory hepatitis B virus.
Topics: Adenine; Adult; Aged; Alanine Transaminase; Antiviral Agents; Creatinine; DNA, Viral; Drug Resistanc | 2010 |
Mineral complexes and vascular calcification.
Topics: Adenine; Alendronate; alpha-Fetoproteins; Animals; Biomarkers; Calcinosis; Calcium; Chemical Precipi | 2009 |
Prevalence and factors associated with renal impairment in HIV-infected patients, ANRS C03 Aquitaine Cohort, France.
Topics: Adenine; Adult; Anti-HIV Agents; Body Mass Index; CD4 Lymphocyte Count; Creatinine; Epidemiologic Me | 2010 |
Histopathology and apoptosis in an animal model of reversible renal injury.
Topics: Adenine; Animals; Apoptosis; Blotting, Western; Diet; Disease Models, Animal; Female; In Situ Nick-E | 2011 |
Systemic disorders of calcium dynamics in rats with adenine-induced renal failure: implication for chronic kidney disease-related complications.
Topics: Adenine; Animals; Calcium Metabolism Disorders; Chronic Disease; Male; Rats; Rats, Inbred F344; Rena | 2010 |
Effects of Gum Arabic in rats with adenine-induced chronic renal failure.
Topics: Adenine; Animals; Anti-Inflammatory Agents; Antioxidants; Chronic Disease; Disease Models, Animal; D | 2010 |
Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities.
Topics: Acute Kidney Injury; Adenine; Adult; Anti-HIV Agents; Biopsy; Drug Administration Schedule; Female; | 2010 |
Changes in the renal function after tenofovir-containing antiretroviral therapy initiation in a Senegalese cohort (ANRS 1215).
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; Glomerular Filtratio | 2010 |
Efficacy and pharmacokinetics of adefovir dipivoxil liquid suspension in patients with chronic hepatitis B and renal impairment.
Topics: Adenine; Adult; Aged; Antiviral Agents; Female; Follow-Up Studies; Hepatitis B, Chronic; Humans; Mal | 2011 |
Add-on combination therapy with adefovir dipivoxil induces renal impairment in patients with lamivudine-refractory hepatitis B virus (J Viral Hepat 2010 Feb 1;17(2):123-9).
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B; Hepatitis B virus; Humans; K | 2011 |
Incidence and risk factors for tenofovir-associated renal function decline among Thai HIV-infected patients with low-body weight.
Topics: Adenine; Adult; Anti-HIV Agents; Body Mass Index; Body Weight; Cohort Studies; Drug Interactions; Fe | 2010 |
Tenofovir-induced kidney disease: an acquired renal tubular mitochondriopathy.
Topics: Acute Kidney Injury; Adenine; Animals; Anti-HIV Agents; Drug Administration Schedule; Glycosuria; HI | 2010 |
Low incidence of renal impairment observed in tenofovir-treated patients.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Case-Control Studies; | 2011 |
Cystatin C and baseline renal function among HIV-infected persons in the SUN Study.
Topics: Adenine; Adult; Anti-HIV Agents; Body Mass Index; CD4 Lymphocyte Count; Cohort Studies; Cross-Sectio | 2012 |
Relationship between renal dysfunction, nephrotoxicity and death among HIV adults on tenofovir.
Topics: Adenine; Adult; Anti-HIV Agents; Cohort Studies; Creatinine; Female; HIV Infections; Humans; Kidney; | 2011 |
Renal impairment in HIV-1 infected patients receiving antiretroviral regimens including tenofovir in a resource-limited setting.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Anti-Retroviral Agents; Female; HIV Infections; HIV-1; Humans | 2011 |
Inorganic phosphate homeostasis in sodium-dependent phosphate cotransporter Npt2b⁺/⁻ mice.
Topics: Adenine; Animals; Blotting, Western; Body Weight; Chromosomes, Artificial, Bacterial; Diet; DNA; Fem | 2011 |
A comparison of tenofovir-associated renal function changes in HIV-infected African Americans vs Caucasians.
Topics: Adenine; Adult; Anti-HIV Agents; Black or African American; Creatinine; Drug Monitoring; Female; Glo | 2011 |
Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B.
Topics: Adenine; Adult; Aged; Antiviral Agents; Biomarkers; Creatinine; Female; Glomerular Filtration Rate; | 2012 |
Nephrogenic systemic fibrosis-like effects of magnetic resonance imaging contrast agents in rats with adenine-induced renal failure.
Topics: Adenine; Animals; Bone and Bones; Contrast Media; Diet; Disease Models, Animal; Gadolinium; Kidney; | 2013 |
The 2012 revised Dutch national guidelines for the treatment of chronic hepatitis B virus infection.
Topics: Adenine; Antiviral Agents; Drug Approval; Drug Resistance, Viral; Female; Guanine; Hepatitis B, Chro | 2012 |
Letter: renal tubular dysfunction during nucleotide analogue therapy in chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Female; Glomerular Filtration Rate; Hepatitis B, Chronic; Humans; Male; O | 2012 |
Osteomalacia due to Fanconi's syndrome and renal failure caused by long-term low-dose adefovir dipivoxil.
Topics: Adenine; Antiviral Agents; Fanconi Syndrome; Hepatitis B, Chronic; Humans; Male; Middle Aged; Organo | 2013 |
Site of methylguanidine production and factors that influence production levels.
Topics: Adenine; Animals; Cyclic N-Oxides; Disease Models, Animal; Electron Spin Resonance Spectroscopy; Fre | 2002 |
Fanconi syndrome and renal failure induced by tenofovir: a first case report.
Topics: Adenine; Anti-HIV Agents; Fanconi Syndrome; Female; HIV Seropositivity; Humans; Middle Aged; Organop | 2002 |
Successful treatment of fibrosing cholestatic hepatitis using adefovir dipivoxil in a patient with cirrhosis and renal insufficiency.
Topics: Adenine; Adult; Antiviral Agents; Bacterial Infections; Cholestasis; Drug Resistance, Microbial; Fib | 2003 |
Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus.
Topics: Acidosis; Adenine; Adult; Anti-HIV Agents; Creatinine; Diabetes Insipidus, Nephrogenic; Drug Monitor | 2003 |
[ON THE ADENINE NUCLEOTIDE CONTENT OF ERYTHROCYTES IN RENAL INSUFFICIENCY].
Topics: Acidosis; Acute Kidney Injury; Adenine; Adenine Nucleotides; Erythrocytes; Humans; Kidney Diseases; | 1964 |
Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failure.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Anti-HIV Agents; Fanconi Syndrome; Humans; Kidne | 2004 |
Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case-control study.
Topics: Adenine; Albuminuria; Antiretroviral Therapy, Highly Active; Case-Control Studies; Cohort Studies; C | 2004 |
2,8-dihydroxyadeninuria: are there no cases in Scandinavia?
Topics: Adenine; Adenine Phosphoribosyltransferase; Heterozygote; Homozygote; Humans; Mutation; Renal Insuff | 2005 |
Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir.
Topics: Adenine; Adenosine Triphosphate; Animals; Antiviral Agents; Breast Neoplasms; Drug Resistance, Neopl | 2007 |
Clinical, biochemical and molecular diagnosis of a compound homozygote for the 254 bp deletion-8 bp insertion of the APRT gene suffering from severe renal failure.
Topics: Adenine; Adenine Phosphoribosyltransferase; Alleles; Base Pairing; Biopsy; Chromatography, High Pres | 2007 |
Unlikely association of multidrug-resistance protein 2 single-nucleotide polymorphisms with tenofovir-induced renal adverse events.
Topics: Adenine; Anti-HIV Agents; Confounding Factors, Epidemiologic; HIV Infections; Humans; Membrane Trans | 2007 |
Early onset of tenofovir-induced renal failure: case report and review of the literature.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Antiretroviral Therapy, Highly Active; Biopsy; H | 2007 |
Alteration of mRNA expression of molecules related to iron metabolism in adenine-induced renal failure rats: a possible mechanism of iron deficiency in chronic kidney disease patients on treatment.
Topics: Adenine; Analysis of Variance; Anemia, Iron-Deficiency; Animals; Antimicrobial Cationic Peptides; Di | 2008 |
Uraemic hyperparathyroidism causes a reversible inflammatory process of aortic valve calcification in rats.
Topics: Adenine; Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Aortic Valve; Blotting, W | 2008 |
Point mutation of the mitochondrial tRNA(Leu) gene (A 3243 G) in maternally inherited hypertrophic cardiomyopathy, diabetes mellitus, renal failure, and sensorineural deafness.
Topics: Adenine; Adult; Cardiomyopathy, Hypertrophic; Deafness; Diabetes Complications; Diabetes Mellitus; F | 1995 |
Effect of magnesium lithospermate B on the renal and urinary kallikrein activities in rats with adenine-induced renal failure.
Topics: Adenine; Animals; Creatinine; Drugs, Chinese Herbal; Kallikreins; Kidney; Male; Rats; Rats, Wistar; | 1993 |
Proof that green tea tannin suppresses the increase in the blood methylguanidine level associated with renal failure.
Topics: Adenine; Animals; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Male; Meth | 1997 |
Influence of adenine-induced renal failure on tryptophan-niacin metabolism in rats.
Topics: 3-Hydroxyanthranilic Acid; Adenine; Animals; Kidney; Kynurenic Acid; Liver; Male; NAD; Niacin; Quino | 2001 |
[The effects of electroporation-mediated erythropoietin (EPO) gene transfer into skeleton muscle on renal anemia].
Topics: Adenine; Anemia; Animals; Disease Models, Animal; Electroporation; Erythropoietin; Gene Expression; | 2000 |
Adefovir nephrotoxicity and mitochondrial DNA depletion.
Topics: Adenine; Antiviral Agents; Clinical Trials, Phase III as Topic; Cyclooxygenase Inhibitors; DNA, Mito | 2002 |